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Abstract
Objective: Autosomal dominant optic atrophy (ADOA) starts in early childhood with loss of visual 
acuity and color vision deficits. OPA1 mutations are responsible for the majority of cases, but in a 
proportion of patients with a clinical diagnosis of ADOA, the cause remains unknown. This study 
aimed to identify novel ADOA-associated genes and explore their causality.
Methods: Linkage analysis and sequencing were performed in multi-generation families and unrelated 
patients to identify disease-causing variants. Functional consequences were investigated in silico and 
confirmed experimentally using the zebrafish model.
Results: We defined a new ADOA locus on 7q33-q35 and identified three different missense variants 
in SSBP1 (NM_001256510.1; c.113G>A (p.(Arg38Gln)), c.320G>A (p.(Arg107Gln)) and c.422G>A 
(p.(Ser141Asn))) in affected individuals from two families and two singletons with ADOA and variable 
retinal degeneration. The mutated arginine residues are part of a basic patch that is essential for 
single-strand DNA binding. The loss of a positive charge at these positions is very likely to lower the 
affinity of SSBP1 to ssDNA. Antisense-mediated knockdown of endogenous ssbp1 mRNA in zebrafish 
resulted in compromised differentiation of retinal ganglion cells. A similar effect was achieved when 
mutated mRNAs were administered. These findings point to an essential role of ssbp1 in retinal 
development and the dominant-negative nature of the identified human variants, which is consistent 
with the segregation pattern observed in two multi-generation families studied.
Interpretation: SSBP1 is an essential protein for mtDNA replication and maintenance. Our data 
established pathogenic variants in SSBP1 as a cause of ADOA and variable retinal degeneration.
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Introduction
Autosomal dominant optic atrophy (ADOA), is one of the most common inherited optic neuropathies 
seen in clinical practice with an estimated prevalence of 1 in 25,000.1 In the majority of cases, ADOA 
is caused by OPA1 gene variants, but several other genes are also known to be associated with 
isolated or syndromic forms of optic atrophy.2 However, a large number of cases remain genetically 
undiagnosed, suggesting variants in novel genes may be involved in the pathogenesis of this disorder. 
The phenotype of ADOA overlaps with Leber hereditary optic neuropathy (LHON; OMIM 535000), 
which is caused by point mutations of mitochondrial DNA (mtDNA) affecting the respiratory chain 
complexes. Hence, it was not surprising that the genes found to be associated with ADOA encode 
mitochondrial proteins. Both are mitochondrial neuropathies and show a markedly variable clinical 
phenotype. However, in most cases, the pathology seems to be limited to a highly specialised group of 
cells within the eye, the retinal ganglion cells.
Proteins of the mtDNA replication machinery are important in maintaining mitochondrial function. The 
“minimal replisome” comprises the mtDNA polymerase gamma, the helicase TWINKLE and the 
mitochondrial single-strand DNA (ssDNA) binding protein SSBP1. Variants in the genes coding for 
POLG and POLG2 as well as TWINKLE have been described to cause chronic progressive external 
ophthalmoplegia (CPEO).3 Surprisingly, no Mendelian disease has been ascribed to date to variants of 
the gene encoding SSBP1.
Here we report on the mapping of a novel locus for ADOA and the identification of heterozygous 
missense variants in SSBP1 as the underlying genetic cause in four unrelated families or single 
patients with inherited optic atrophy and subsequent retinal degeneration.
Methods
Study population and clinical investigation
Four unrelated non-consanguineous families were identified from a cohort, which was negative for 
OPA1 and the three most common LHON mutations, namely m.3460G>A (MTND1), m.11778G>A 
(MTND4) and m.14484T>C (MTND6) (Fig 1A). Written informed consent was obtained. The study had 
ethical and institutional approval (Moorfields Eye Hospital NHS Foundation Trust (REC 13/YH/0310) 
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and Cardiff & Vale University Health Board, Wales (REC 02/09/01)) and complied with the Declaration 
of Helsinki. Eleven affected individuals from three families (Family 1 (GC13572), Family 2 and Family 
3 (GC17999)), underwent full ophthalmic examination, including imaging (Fig 2) and electrophysiology 
of the visual system (Fig 3). In addition, the medical records of eight family members from three 
generations of Family 1 and the singleton from Family 4, were reviewed.
Electrophysiological investigation of Families 1 and 3 included pattern and flash visual evoked 
potential (PVEP; FVEP) and pattern and full-field electroretinography (PERG; ERG) testing, performed 
to incorporate the Standards of the International Society for Clinical Electrophysiology of Vision 
(ISCEV). An extended protocol for photopic On-Off ERG and short-wavelength flash (S-cone) ERG 
were also performed.4–7 Family 2 underwent flash VEPs and pattern reversal VEPs to a 30-minute 
check in 3 of 4 cases. Full-field ERGs (maximum DA and LA flash strength 2.25 cd.s.m-2) were 
performed in all 4 individuals; large field pattern ERGs were analysed in one. The proband of Family 4 
did not have electrophysiology assessment.
Molecular genetics
Blood samples were collected from 35 individuals (13 affected and 22 unaffected) from three 
generations of Family 1 and eight individuals (four affected and four unaffected) from two generations 
of Family 2. In parallel, individuals 4-12 of Family 1 and 2-3 of Family 3 were recruited and analyzed 
by whole-genome sequencing (WGS) as part of the 100,000 genomes project.
Linkage analysis in Family 1
In light of the clear autosomal dominant inheritance pattern of the disease in Family 1, and following 
exclusion of disease associated variants in the OPA1 gene, DNA samples were subjected to SNP 
array genotyping (Affymetrix GeneChip Human Mapping 10K Array). Linkage analysis was performed 
assuming complete penetrance and a disease allele frequency of 0.0001. Multipoint LOD scores were 
calculated using the program ALLEGRO (Fig 1B).8 Haplotypes on chromosome 7 were reconstructed 
from microsatellite genotype data (Fig 4).9
DNA enrichment and sequencing
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Enrichment of the linkage interval and subsequent sequencing were performed as described 
elsewhere.10 We used the Roche NimbleGen 385K custom sequence capture array with a capacity of 
up to 5 Mb of target sequence. The exon-based design included all exons of the protein-coding genes, 
including 100bp of flanking intron sequence and 1 kb of the promoter regions, and known miRNAs 
within the critical interval (GRCh37/hg19). Final coverage of the design was 97.9%. From the enriched 
DNA samples, we generated paired-end libraries and sequenced them on an Illumina GA IIx device 
with a read length of 2 x 36 bp.
For data handling and analysis, we used our in-house database and analysis tool kit VARBANK 2.0 
(https://varbank.ccg.uni-koeln.de/varbank2/). Reads were demultiplexed with bcl2fastq (v1.8.4) and 
aligned with bwa aln -t 4 -q 15 (v0.7.15) against the GRCh38 reference sequence.11 Duplicates were 
removed using Picard (http://broadinstitute.github.io/picard/). This was followed by local realignments 
and base quality score recalibration (GATK v3.6).12 Single nucleotide variants (SNVs) and short 
INDELs were called by combining the information obtained with three different software packages, 
namely Platypus (v0.8.1), GATK HaplotypeCaller (v3.6) and SAMtools mpileup (v1.6).12–14 For the 
assessment of variants regarding frequency and pathogenicity, we used in-house software that 
automatically queries several external databases like dbSNP (b150), gnomAD (r2.0.1) 
(http://gnomad.broadinstitute.org/), ClinVar (V2017-02-17), dbNSFP (v3.4a), ENSEMBL (b90), and 
HGMD-prof (2017-02).15–19 Moreover, we analysed 1133 exomes or Mendeliomes (TruSight™ One 
disease-associated gene panels from Illumina) of unrelated human individuals sequenced at the CCG 
to build an in-house database of variants that allowed us to filter out common technical artefacts. 
Default settings for variant filtering with the graphical user interface of VARBANK 2.0 were the 
following: read AF>25%; max gnomAD population AF<1%; in-house population AF<5%; QD>5; 
FS<40; ReadPosRankSum>-5; MQ>50; MQRankSum>-5; quorum level SNV=2; quorum level 
INDEL=1; splice site score change<-15%; TIS [translation initiation site] score change<-15%.20,21
For the validation of the mutation detected in SSBP1, co-segregation analyses in families and 
mutation screening in further patients, we performed Sanger sequencing following standard protocols.
Sanger sequencing 
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Furthermore, 31 unrelated probands (including Families 3 and 4) who underwent prior OPA1 gene 
screening and screening for three most common LHON mutations were selected for direct Sanger 
sequencing of all coding exons (including intronic splice junctions) using standard reagents and 
protocols (primers available on request). 
Interpretation of sequence variants at protein level
To study the conservation of mutated amino acid residues, we performed multiple alignments of 
SSBP1 homologous proteins using ClustalW.22 Information about the domain structure was obtained 
from UniProtKB - Q04837 (SSBP_HUMAN). To predict the consequences of the missense mutations 
in the three-dimensional space, we analyzed the structure with pdb code 1S3O, which is an 
amendment of the original dimeric human SSBP1 X-ray structure 3ULL, using the advanced program 
WebLab™ ViewerPro™ from Molecular Simulations Inc.23,24
SSBP1 and OPA1 staining of mouse retina
Whole eyes from adult mice were fixed in Davidson’s fixative for 18 hours at 4°C, dehydrated and 
cleared using a graded series of alcohol followed by xylene, and embedded in paraffin wax. Standard 
protocols for sectioning, antigen retrieval and blocking were carried out. Ssbp1 antibody (Abcam 
ab26205) and OPA1 antibody (Abcam ab 42364) were diluted in PBS+1% normal serum and 
incubated overnight at 4°C. Sections were incubated with biotinylated secondary antibody (Stratech, 
Newmarket, UK) diluted in PBS/T for 1h at room temperature, followed by ABC reagent (RTU 
Vectastain ABC reagent, PK-7100, Vector laboratories, Peterborough, UK) for 30 minutes at room 
temperature and then DAB substrate (DAB substrate kit for peroxidase SK-4100, Vector laboratories), 
and counterstained with Harris haematoxylin (Thermo Scientific). Images were acquired using a Leica 
DMRA2 microscope with QWin software. 
Cultured SH-SY5Y cells
SH-SY5Y neuroblastoma cells were cultured on coverslips in 24 well plates seeded at a density of 
5x103 cells per well and allowed to establish overnight, as per published protocols. Mitochondria were 
labelled using MitoTracker red CMXROS (Invitrogen, Paisley UK) at 100 nM for 10 minutes in full 
culture medium (50:50 MEM:Ham’s F12, 15% FBS, 2mM glutamine, 100 U penicillin / 0.1 mg/ml 
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streptomycin, NEAA)  at 37°C. Processing was as per established protocols. In addition, the cells were 
incubated with Anti-SSBP1 (ab26205, Abcam) and TFAM antibody (sc-166965, Santa Cruz), as per 
standard protocols, and stained with Hoechst 33342 (Thermofisher, UK) before mounting coverslips 
using ProLong® Gold Antifade Mountant (Thermofisher, UK) and sealing with nail polish. Images were 
acquired using a DM6000 Leica microscope (Leica, Wetzlar, Germany) with a 63X/1.4 oil Plan 
apochromat objective. 
Generation of constructs, mRNA synthesis, morpholinos and microinjection into zebrafish
A full-length cDNA clone (IRBOp991A1161D; zgc:110325) was obtained from Source Bioscience Inc 
to generate a zebrafish SSBP1 expression construct. The SSBP1 open reading frame (orf) was 
excised with EcoRI and XbaI from this EST clone and ligated into the pCS2+ expression vector.25 In 
order to eliminate an alternative start codon in the 5’-UTR of this construct, side directed mutagenesis 
was performed using the primer pair 5’-CTGGATTTTCTGGACGACATATCGGTAAAC-3’, 5’-
GTTTACCGATATGTCGTCCAGAAAATCCAG-3’. Further PCR-based site directed mutagenesis was 
applied to this source construct for th  generation of the three mutated SSBP1 versions using the 
following primers, for mutation p.(Arg38Gln): Mut1-GA-F 5’-
CAGATTCTTGGGCAAGTCGGGCAAGAC-3' and Mut1-GA-R 5’-
GTCTTGCCCGACTTGCCCAAGAATCTG-3', for mutation p.(Arg107Gln): Mut2-GA-F 5’-
GTATGTAAAGAAAGGGTCTCAGATTTTTGTGGAAGGAAAG-3' and Mut2-GA-R 5’-
CTTTCCTTCCACAAAAATCTGAGACCCTTTCTTTACATAC 3', for mutation p.(Ser141Asn): Mut3-GA-
F 5’-GATAATATTGTGTTTCTAAATGAAAACCTGCGGGACCAG-3' and Mut3-GA-R 5’-
CTGGTCCCGCAGGTTTTCATTTAGAAACACAATATTATC-3'. Sequence integrity of all generated 
SSBP1 constructs was evaluated via Sanger sequencing. Capped mRNA was prepared after plasmid 
linearization with NotI, using the mMessage mMachine Sp6 Kit (ThermoFisher).
The following antisense morpholino-oligonucleotides (MO) were obtained from Gene Tools Inc.: ATG-
MO 5’-GCGTTTCTCAACATCTCTGCTGCGT-3’, ATG-5mmMO 5’-
GCATTGCTCATCATCTGTGCTGCGA-3’, splice-MO 5’- TACTTCTTGTATTGTTACCTGTGCG-3’, 
splice-5mmMO 5’-TAGTTCTAGTATTCTTACGTGTGCA-3’. The MOs were diluted in 1xDanieu’s 
buffer to a final concentration of 0.2 pmol/nl, the mRNAs were diluted accordingly to a working 
concentration of 75pg/nl (Fig 5 L – L’’), or in the context of Fig 5 L’’’ to a concentration of 100pg/nl (wt-
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RNA single injection) or 50pg/nl each (wt- and mutant-RNA co-injections). Injections were performed 
in volumes of 1 to 1.5 nl into zebrafish embryos at the 1-2 cell stage as described. Single or co-
injections were performed as described in volumes of 1 to 1.5 nl into zebrafish embryos at the 1-2 cell 
stage as described.26,27
Immunohistochemistry, in situ hybridization and phenotype recording in zebrafish
Cryo-sectioning of 14µm slices followed by fluorescent immunohistochemistry was performed on a 
Leica Cryostat CM1850. As primary antibodies rabbit anti-Acetylated Tubulin (Cell Signaling 
Technologies, 5335T) and mouse anti-Elavl3/Huc (Thermo Fisher Scientific, A-21271) were used in 
dilutions of 1:500 in blocking medium. As secondary antibodies goat-anti-mouse AlexaFluor-488 
(ThermoFisher Scientific, A-11001) and goat-anti-rabbit AlexaFluor-555 (ThermoFisher Scientific, A-
21428) were used in dilutions of 1:1000. After mounting with Dapi inoculated Moviol, samples were 
imaged on a Zeiss LSM710 confocal microscope.
Whole-mount in situ hybridizations were performed as previously described.28 Stained specimens 
were cleared in 80% glycerol/PBS for several hours followed by mounting in 100% glycerol for image 
capturing on a Zeiss AxioImagerM.2 compound microscope using a 10x objective. Riboprobes of isl1 
and atho7 cDNA were generated and used as described.29,30 Calculation of statistical significance 
among compared groups of certain experimental conditions was done via a χ2-test utilizing the 
programming language R. To allow for χ2-testing in this context algorithmic operations were performed 
with the three sub-groups (I) strong, (II) medium, (III) weak+none (sub-groups weak and none of the 
chart in Fig 5 L – L’’’ were merged into a single phenotypic class).
Results
Clinical examination of affected individuals with SSBP1 mutation
Clinical findings are summarised in Supplementary Table 1. Where available, detailed findings are 
described below.
Family 1
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All affected individuals presented with decreased visual acuity in early childhood due to bilateral optic 
atrophy, with no additional ocular structural abnormalities. Optic atrophy was documented in isolation 
(subjects 3-16, 4-3, 4-7, 4-8 and 5-12), or before the development of retinal vessel attenuation, or 
retinal pigmentary changes (subjects 3-8, 4-12, 4-14, 4-18, 5-2 and 5-5). All examined patients had 
bilateral optic atrophy and reduction of the peripapillary retinal nerve fibre layer (RNFL) (Fig 2A and 
2B) with hypoplastic optic nerves noticed in patients 4-12 and 4-14 (Fig 2A). Retinal examination 
revealed different degrees of vessel attenuation, abnormal appearance of the fovea, and retinal 
pigmentary changes in the mid-periphery in individuals 4-12, 4-14, 4-18, 5-5 (Fig 2D and 2E). OCT 
confirmed optic atrophy and showed retinal atrophy and a thin choroid in all patients; with a focal 
disruption of photoreceptors at the fovea with intact RPE in patients 4-18, 5-5 and 5-12 (Fig 2C). In 
addition, hypothyroidism (subjects 4-12, 4-14, 4-16 and 4-18) and a renal disorder, including renal 
failure (subjects 3-8, 4-3 and 4-18), were documented. One individual (5-2) was reported to have 
nystagmus.
Family 2
Most affected members presented with decreased visual acuity in middle and late childhood, with one 
member being affected in adolescence, and one in mature adulthood (4th decade). All examined 
patients had bilateral optic atrophy, with pigment mottling in the foveal region noticed in individuals 2-
2, 2-3 and 3-4 (Fig 2D). Retinal examination did not reveal vessel attenuation and visual acuity was 
better overall compared to Family 1. The affected individuals did not have any systemic disorders.
Family 3
The proband of Family 3 was the only affected individual with bilateral optic atrophy diagnosed at the 
age of seven years. In adolescence he was noted to have retinal changes. At the age of 57 years, 
fundus examination showed bilateral optic atrophy with mild attenuation of arterioles and mild retinal 
pigment epithelium changes around the arcades (Fig 2D and 2E). OCT showed photoreceptor outer 
segment and outer nuclear layer loss with intact RPE (Fig 2C). Hypothyroidism was recorded in the 
proband and two non-affected siblings.
Family 4
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The singleton from Family 4 was diagnosed with bilateral optic atrophy in his second decade and 
subsequently examined at the age of 45 years. 
After reviewing medical records, a chronological order of ophthalmological changes were noticed: 
initially all patients presented and were diagnosed with optic atrophy, followed by retinal vessels 
attenuation and pigmentary retinal changes documented the latest (Supplementary Table 1). The 
range of follow up period was from 4 to 47 years. 
Electrophysiology
Electrophysiology findings are described below with examples (Fig 3) and a summary (Supplementary 
Table 1).
Pattern reversal VEPs were undetectable in the two oldest patients tested in Family 1 (4-12 and 4-14; 
46 and 45 years), in one younger member of Family 2 (3-4; 19 years) and showed delay and marked 
reduction in the proband of Family 3 (2-3). Other cases showed reduced pattern VEPs without delay 
(Family 1: 5-2), had an abnormal bifid or broad waveform (Family 1: 5-5 and Family 2: 2-2) or a 
delayed major positive peak (Family 1: 5-12 and 2-3). Flash VEPs were undetectable in two cases 
(Family 1: 4-14 and Family2: 3-4). Pattern ERGs were undetectable in the 2 oldest patients of Family 
1, suggesting macular dysfunction, and were not recordable due to nystagmus in one other case 
(Family 1: 5-2). PERG N95:P50 ratio was subnormal in four cases (Family 1: 5-5, 5-12 and 3-4, and 
Family 3: 2-3) and P50 was additionally of abnormal short peak time in two (Family 1: 5-5 and 5-12) 
and, with additional mildly reduction in Family 1: 5-5. 
Full-field ERGs were abnormal in four of five affected individuals in Family 1 and in the proband of 
Family 3, consistent with generalised rod and cone photoreceptor dysfunction, most severe in case 4-
14, and affecting rods slightly more than cones in the four with milder ERG abnormalities (Family 1: 4-
12, 5-2, 5-5 and Family 3: 2-3). On-Off ERG b-waves were delayed in two cases with relative 
preservation of d-waves, analysable in 3 of 3. The flash ERGs in the youngest patient of Family 1 and 
in 4 of 4 in Family 2 revealed no abnormality.
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The VEPs and PERG obtained in Family 1: 5-5 at the age of 18 years, were reasonably stable when 
repeated at the age of 26 years, but full-field ERGs showed evidence of worsening rod and cone 
system function.
In summary, there was PERG and VEP evidence of optic nerve/retinal ganglion cell dysfunction in four 
cases without macular cone dysfunction (Family 1: 5-5, 5-12, 3-4 and Family 3: 2-3); severe flash VEP 
and/or pattern VEP abnormalities suggesting optic nerve dysfunction in 4-14 (Family 1) and likely 4-12 
(Family 1), but with PERG evidence of additional macular dysfunction in both, and in case 5-2 (Family 
1), an abnormal PVEP that may have related to optic nerve dysfunction and/or nystagmus. The ERGs 
in Families 1 and 3 indicated additional generalised photoreceptor involvement in all but the youngest 
individual, with evidence of severe photoreceptor (N=1) or rod-cone dystrophy (N=4). In one individual 
monitored over eight years (Family 1: 5-5), optic nerve/retinal ganglion cell dysfunction was stable, but 
there was ERG evidence of a mildly progressive rod-cone dystrophy. 
Mapping of a new locus for ADOA in Family 1
Among our patients without mutations in genes known to be associated with optic atrophy, we 
ascertained a large family with 23 affected individuals in five generations displaying an autosomal 
dominant mode of inheritance (Fig 1A). Genome-wide linkage analysis using 10K SNP array genotype 
data of 13 individuals (boxed IDs) established a new disease-associated locus on the long arm of 
chromosome 7 based on a significant LOD score of 3.61 (Fig 1B). We then performed fine-mapping 
using microsatellite markers from the linkage region. A haplotype analysis of the extended pedigree 
revealed recombined disease haplotypes in individuals 4-3 and 4-18, defining a critical interval of ~9.5 
Mb between the Marshfield marker GATA30F12 and D7S3044 (Fig 4). A partial re-analysis of the 
family using high-density SNP arrays (Illumina 317 K BeadChip) slightly reduced this interval with the 
final flanking markers being rs7800258 (GRCh37 (hg19) chr7:135,836,989) and rs10280300 (GRCh37 
(hg19) chr7:145,209,049).
Identification of mutations in SSBP1
To identify the underlying gene variant in Family 1, we enriched all protein-coding genes (>100) and 
known miRNAs within the critical interval by using Roche NimbleGen’s 385K custom sequence 
capture array. DNA of the two recombinant affected females 4-3 and 4-18 from Family 1 was 
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subjected to target enrichment and sequencing. Enrichment factors of 206-fold and 567-fold were 
achieved for 4-3 and 4-18, respectively, as determined by quantitative PCR of four control loci at the 
array in a comparison of enriched versus non-enriched DNA. The two libraries were subjected to 
massively parallel sequencing (Illumina GA IIx), resulting in approximately 2,828.6 Mb and 2,606.0 Mb 
of mapped sequences for the two individuals analyzed. The average coverage of the 671,414 bp of 
target sequences was higher than 270x in both samples. Called variants were filtered using the latest 
version of VARBANK’s graphical user interface (https://varbank.ccg.uni-koeln.de/varbank2) with 
default parameters set to focus on rare high-quality variants altering the protein sequence or showing 
impairments of splice and translation initiation sites. This resulted in a single variant that was identical 
in both samples, namely a heterozygous missense mutation in SSBP1 (NM_001256510.1; c.320G>A 
(p(.Arg107Gln)). Pathogenicity rank scores from 31 algorithms, (including CADD, DANN, Eigen, 
FATHMM, fitCons, GenoCanyon, Gerp, LRT, M-CAP, MetaLR, MetaSVM, MutationAssessor, 
MutationTaster, MutPred, phastCons, phyloP, Polyphen2, PROVEAN, REVEL, RF, SIFT, SiPhy, 
VEST3) were taken from the dbNSFP v.3.4a database.17 Rank scores are always in the range 
between 0 and 1 and the meaning of a rank score of 0.9 indicates that it is more likely for the SNV to 
be damaging then 90% of all potential non-synonymous SNVs. The median of all 31 rank scores for 
this variant was 0.75. 
Subsequent Sanger sequencing of 31 unrelated OPA1 and mtDNA negative patients revealed three 
further individuals with a variant in SSBP1. In 2 patients, we identified the variant c.113G>A 
(p.(Arg38Gln)) (Families 2 and 3) and in the third (Family 4), the variant c.422G>A (p.(Ser141Asn)) 
(Fig 6A). The variants cosegregated perfectly with disease in all available individuals of Families 1 and 
2. All variants are absent from the gnomAD dataset (comprising over 240,000 alleles).
As part of the 100,000 genomes project, individuals 4-12 of Family 1 and 2-3 of Family 3 were 
analyzed by whole-genome sequencing as described previously.31 To confirm the SSBP1 variants to 
be the most likely disease-associated variants in these individuals, we first excluded all candidate 
variants occurring in a virtual panel of genes previously shown to be associated with posterior 
segment disorders or inherited optic neuropathies 
(https://panelapp.genomicsengland.co.uk/panels/186/ and 
https://panelapp.genomicsengland.co.uk/panels/307/) and all known mtDNA mutations. Subsequent 
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analysis on the genomic region defined by the linkage interval in Family 1, confirmed the previously 
identified SSBP1 variant as the most likely disease-causing variant. 
SSBP1 encodes a single-stranded DNA binding protein which is essential for mtDNA replication and 
maintenance.32 All variants are located in the functionally relevant single strand DNA binding domain 
of SSBP1 and affect sites that are strictly conserved in vertebrates (Fig 6B and 6C). Notably, residues 
Arg38 and Arg107 are each part of the basic patch B consisting of four basic amino acid side chains 
important in supporting the protein/ssDNA interaction. Loss of a positive charge here may decrease 
the ssDNA affinity at a substantial degree.24 The serine at position 141 is the last residue of a ß-
extended strand located nearby at the flexible C-terminus of the protein (Fig 6D) where mutation to 
asparagine may disturb tetramer formation. 
PCR-free WGS preserves the dosage of the genome enabling detection of copy loss and gain. In 
addition, the complete coverage of >95% of the genome including the full mtDNA by 150bp paired end 
reads enables the accurate characterization of structural variant breakpoints.33 Therefore, by 
interrogating mtDNA read depth and split/chimeric read data we were not able to demonstrate any 
evidence of accumulations of large or small mtDNA deletions in the WGS data of individuals from the 
family 1 and family 3 (data not shown). This was consistent with long-range PCR studies of blood DNA 
from 3 affected individuals (5-5 and 5-12 of family 1 and 2-3 of family 3) with no evidence of mtDNA 
deletions in the blood DNA samples.
SSBP1 expression in mouse and zebrafish and consequences of ssbp1 knock-down and 
forced expression of its mutant variants on zebrafish development
To demonstrate the expression of SSBP1 in the eye, we performed DAB immunohistochemistry and 
confirmed that SSBP1 is abundant in all the layers of the retina (Fig 7). Furthermore, we found it co-
localised with mitochondria and mitochondrial nucleoids in SH-SY5Y cells labelled with mitotracker 
(Fig 8B) and anti-TFAM (Fig 8F). To study whether the role of SSBP1 in supporting retinal development 
and/or maintenance is evolutionary conserved, we knocked it down in zebrafish, a widely used 
vertebrate model system for biomedical research, including mitochondrial biology and 
neurodegeneration.34 During development, zebrafish ssbp1 is ubiquitously expressed, including the 
retina, as formerly revealed via whole mount in situ hybridizations of embryos up to five days post 
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fertilization (which corresponds to birth in mammals) (https://zfin.org/ZDB-PUB-040907-1). Injection of 
fertilized zebrafish eggs with two different antisense morpholino oligonucleotides to block the 
translation or splicing of endogenous ssbp1 mRNA resulted in strongly reduced expression of the 
developmental regulator genes isl1 and atoh7 in RGC precursors, while other expression domains of 
isl1 in the developing brain (Fig 5A-F) and overall embryo morphology (Fig 5G) were normal.35 Later, 
non-photoreceptor cells both in the ganglion cell layer (GCL) and, most likely secondarily, in the inner 
nuclear layer (INL) displayed compromised neuronal specification, while cell numbers in both layers 
were unaltered (Fig 5J,K). Furthermore, the optic nerve, consisting of RGC axons, was much thinner 
(Fig 5J,K), consistent with the axonal deficiencies of peripheral neurons formerly reported for zebrafish 
ssbp3 morphants.36–38 In contrast, the respective 5-mismatch ssbp1 morpholino controls had no 
effects (Fig 5J,L,L’), while re-introduction of ssbp1 mRNA via co-injection with the ssbp1 splice 
morpholino led to a significant alleviation of the retinal defects (Fig 5L’). These alterations clearly affect 
the initial specification, rather than the later maintenance of RGCs, as seen in human patients (see 
also Discussion). However, both result in similar RGC and optic nerve defects, suggesting that the 
identified human missense mutations have loss of SSBP1 function effects.
Dominantly inherited loss-of-function mutations as in the case of the human patients could either be 
due to haploinsufficiency or dominant negative (antimorphic) effects. In order to distinguish between 
these two possibilities, we again employed the zebrafish system to study the effects of the 
corresponding mutant ssbp1 mRNAs when exogenously applied.  Strikingly, all tested mutant versions 
(p.(Arg38Gln), p.(Arg107Gln) and p.(Ser141Asn)) caused a reduction in retinal atoh7 expression, both 
when administered singly to compete with the endogenous wild-type Ssbp1, and when administered 
together with equimolar amounts of exogeneous wild-type ssbp1 mRNA into ssbp1 morphants (Fig 
5H,I,L’’,L’’’), suggesting that the mutant versions have a dominant negative effect on wild-type Ssbp1. 
Discussion
Heterozygous missense variants in the SSBP1 were identified in patients with a form of bilateral optic 
neuropathy, commonly associated with additional and subsequent variable pigmentary retinal 
changes. This is the first report of Mendelian disease caused by variants in SSBP1 and highlights the 
link between SSBP1 dysfunction and mitochondrial-related optic neuropathy.
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Although optic neuropathy is a prominent ophthalmological feature of mitochondrial diseases, it is not 
universal and phenotypic variation, such as retinal degeneration with pigmentary retinal changes or 
chronic progressive ophthalmoplegia, can be seen in patients with mitochondrial disorders. Retinal 
degeneration can be accompanied by vascular attenuation, which becomes more noticeable with 
disease progression and increasing patient age.39 Pigmentary changes can be seen in CPEO, 
specifically in Kearns-Sayre syndrome.40 However these changes can also be detected among 
patients with MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like 
episodes), MIDD (maternally inherited diabetes and deafness), MNGIE (mitochondrial 
neurogastrointestinal encephalomyopathy), OPA1 mutations, MILS (maternally inherited Leigh 
syndrome) and NARP (neuropathy, ataxia and retinitis pigmentosa).41 Recently, optic atrophy with 
vessel attenuation and retinal degeneration has been reported in a patient found to harbour ACO2 
mutation.42 A similar phenotype of both optic atrophy and pigmentary retinal changes was a common 
feature in the current study. In some of the cases reported here the retinal changes was very mild, as 
in the younger members of Family 1 and Family 3, detected only on detailed fundus examination or 
retinal imaging, and on ERG testing. However, in Family 1 optic atrophy and pigmentary retinal 
changes were prominent features; but absent in Family 2. The link between mitochondrial dysfunction 
and retinal degeneration may relate to the production of reactive oxygen species (ROS), which is a 
normal metabolic process during the phagocytosis of photoreceptor outer segments in the retina. If 
mitochondrial function is impaired, the retinal pigment epithelium (RPE) may be exposed to higher 
levels of ROS, leading to cumulative oxidative damage to the RPE and subsequently manifesting as 
pigmentary retinopathy.
In addition to the optic neuropathy and retinal degeneration some affected individuals in Family 1 and 
Family 3 were diagnosed with renal disease and hypothyroidism although at least one unaffected non-
carrier of the variant was also reported to also have hypothyroidism. Other studies are necessary to 
explore the relationship between SSBP1 variants and additional systemic disease features. 
Furthermore, as we could not perform segregation analysis in singleton case from Family 4, we 
assume that identified variant is causal. By analysing WGS data and long-range PCR studies on blood 
DNA of affected individuals from two families, we ruled out the accumulation of large-scale mtDNA 
rearrangements, in particular mtDNA deletions. However, we did not have access to skeletal muscle 
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tissue to further study whether SSBP1 mutations results in mtDNA instability and the link with the 
underlying disease pathophysiology.
In surveying our current knowledge of the biochemical components of the mtDNA replication 
machinery, it is striking that mutations in POLG/POLG2 and TWNK lead to progressive 
ophthalmoplegia while mutations in SSBP1 cause a different phenotype.43 All four gene products form 
together on the replication machinery therefore one might expect highly overlapping phenotypes. It 
may be that the role of SSBP1 is more cell-type specific.
SSBP1 is essential for mtDNA replication and maintenance, its downregulation or dysfunction may be 
expected to affect mtDNA copy number, resulting in mitochondrial morphological and functional 
changes, including accumulation of reactive oxygen species in mitochondria. 44 It is likely that biallelic 
loss of gene function (knock out) would be incompatible with life 
(http://www.mousephenotype.org/data/genes/MGI:1920040). However, the ExAC and gnomAD 
datasets include heterozygous carriers of predicted LOF variants and a probability of loss of function 
intolerance score (pLI) of 0.00 (gnomAD) for SSBP1 suggesting that haploinsufficiency is unlikely to 
be associated with paediatric onset Mendelian disease.45 In addition, recently, it was reported that a 
heterozygous start loss variant in the SSBP1 co-segregated with sensorineural hearing loss in a large 
family harbouring the variable penetrance m.1555A>G maternally inherited deafness variant. The 
authors stated that SSBP1 variant leads to reduced SSBP1 level and perturbation of mtDNA 
metabolism, but the presence of an SSBP1 start loss mutation alone was not associated with disease 
unless in conjunction with the m.1555A>G variant.46
The variants reported herein are missense changes that affect amino acid residues in close proximity 
in the SSBP1 tertiary structure. Two of them are likely to weaken the interaction with ssDNA as they 
partially disrupt a basic patch, through which ssDNA binding is accomplished. For p.(Ser141Asn) we 
propose an interference with tetramer formation as the most likely consequence as it was shown that 
substitution of that serine by cysteine results in a covalent linkage of the dimers within the tetramer.24 
Thus the Ser141 is exposed and obviously situated in a region of the structure involved in dimer 
contacts underlying the tetramer formation. In addition p.(Arg38Gln) is found in two not knowingly 
related families suggesting it may be a recurrent mutation representing a hotspot for mutation. 
Therefore, we hypothesise that these variants in SSBP1 act as dominant-negative variants which is 
Page 19 of 66
John Wiley & Sons
Annals of Neurology
For Peer Review
18
further supported by our functional analyses performed in zebrafish embryos. Here, both antisense-
mediated inactivation of the endogenous ssbp1 mRNA as well as administration of exogenous mRNAs 
carrying the identified human mutations led to compromised development of RGCs, pointing to an 
essential role of SSBP1 in retina development and a dominant-negative nature of the human 
mutations, in line with their dominant inheritance. Unfortunately, due to the temporal restriction of 
morpholino-based ssbp1 knockdown in zebrafish (being only effective for approximately 3 days after 
administration), and the pre-weaning lethality of homozygous Ssbp1 null mutants in the mouse 
(http://www.mousephenotype.org/data/genes/MGI:1920040), we could not investigate possible later 
retinal degeneration in these animal models. However, the combination of early RGC specification 
defects in zebrafish and later RGC degeneration in human is nicely in line with the concept of shared 
genetic control of early specification and later maintenance of neurons, as not only reported in the 
context of retinal development and degeneration, but also for dopaminergic neurons and Parkinson’s 
disease.47–49
To summarise, we report detailed genetic, clinical and electrophysiological features in similarly 
affected individuals from four families with early onset bilateral optic neuropathy and subsequent 
retinal degeneration. This study identifies missense variants affecting highly conserved amino acid 
residues in the ssDNA binding domain of SSBP1 and their association with disease.
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Figure legends
FIGURE 1: Mapping of a new ADOA locus.
(A) Pedigrees of four families with ADOA of previously unknown underlying genetic cause. An asterisk 
indicates family members from whom DNA was available. (B) Schematic representation of genome-
wide LOD score calculations after 10K array SNP genotyping of 13 samples from family 1 (boxed ID 
numbers). LOD scores calculated with ALLEGRO are given along the y-axis relative to genomic 
position in cM (centi Morgan) on the x-axis. Note the highest peak (LOD = 3.61) in a region on 
chromosome 7.
FIGURE 2: Colour optic nerve head, fundus, fundus autofluorescence (FAF) and OCT composite of 
affected members (single eye selected).
(A) Colour image of the optic nerve head shows different degrees of optic atrophy. (B, F) OCT B-scan 
of the disc (top) and circumpapillary area (bottom) showing atrophic optic nerve head and RNFL 
thinning; (C, F) OCT scans through macula showing thin atrophic retina with focal loss of the outer 
retina. (D) Fundus colour photographs from the affected family members:  various degrees attenuated 
vessels and pigmentary changes in Family 1: 4-12, 4-14, 4-18, 5-5 Family 2: 2-2, 2-3 and singleton 
case of Family 3 (E) FAF of the patient 4-12 (F1) showing an area of decreased autofluorescence 
around the vessels arcades more prominent on the superior part. 4-14 (F1) FAF shows patches of 
hypoautofluorescence including atrophic areas in posterior pole with hyperautofluorescence area next 
to optic disc. 4-18 (F1) FAF indicates an increased autofluorescence in fovea. FAF of 5-5 (F1) shows 
hypofluorescent patchy pattern in midperipheral retina and increased autofluorescence in the fovea. 5-
12 (F1) normal FAF. 2-3 (F3) diffuse hyperautofluorescence in posterior pole with 
hypoautofluorescence around the vessels arcades and in fovea.
FIGURE 3: Pattern ERG (PERG) and pattern reversal and flash VEP (PVEP; FVEP) recordings for the 
right eyes of 6 affected individuals, including 8 years after baseline testing in case 5-5 of Family 1.
All recordings showed a high degree of inter-ocular symmetry. The age of each individual at the time 
of recording is indicated. All waveforms are superimposed to demonstrate reproducibility. It was not 
possible to obtain a PERG recording in case 5-2 due the effects of eye movements. Recordings from a 
representative control subject are shown for comparison (control). PERG is undetectable (4-12 and 4-
14), shows a P50 component of short peak time (5-5 and 5-12) and a reduced N95:P50 ratio (5-5, 5-
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12 and Family 3 2-3). PVEPs are abnormal in all cases and FVEPs undetectable in one (4-14). See 
text for details. Full-field ERGs from the right eyes in each of 6 cases that underwent International 
standard ERG testing, with additional On-Off and S-cone ERGs, and representative control recordings 
from a healthy subject for comparison (control). Dark-adapted (DA) ERGs are shown for white flashes 
of 0.01, and 10.0 cd.s.m-2. Light-adapted (LA) ERGs are shown for white flashes of 3.0 cd.s.m-2 (30Hz 
and 2Hz). Traces are superimposed to demonstrate reproducibility (with exception of On-Off ERG in 5-
2). Broken lines replace blink artefacts that occur soon after b-waves in DA10 ERGs and in the On-Off 
ERGs in Family 3 2-3.  All 5 cases show evidence of generalised retinal dysfunction with either similar 
severity of rod and cone involvement (4-14) or rod-cone dystrophy (4-12; 5-2; 5-5, Family 3 2-3). 
There is evidence of progression in 5-5 between the ages of 18 and 26 years.
FIGURE 4: Identification of recombination breakpoints in family 1.
Reconstruction of haplotypes was performed using genotype information of 14 STR markers from the 
linkage region on chromosome 7q33-q35. The disease haplotype is shown in red. Recombination 
events are visible in individuals 4-3 and 4-18 (boxed marker alleles). They define a ~9.5 Mb critical 
interval for the disease locus. The flanking markers are GATA30F12 and D7S3044 at the proximal and 
distal end, respectively. Markers within the critical interval are printed in bold type.
FIGURE 5: Knock-down of ssbp1 as well as expression of mutant ssbp1 versions result in impaired 
initiation of retinal ganglion cell (RGC) differentiation and retinal integrity in zebrafish.
Expression of the RGC markers Isl1 (A-C) and atho7 (D-F, H, I) was visualized by whole-mount RNA 
in situ hybridization in eyes of zebrafish embryos injected with either antisense Morpholino-
oligonucleotides against ssbp1 (B, C, E, F) or with mRNA of distinct ssbp1 alleles (H, I) as indicated at 
30 hours post fertilization (hpf). Arrows in A to C point at isl1 positive RGCs.  Insets in E and F show 
retinas of embryos injected with cognate control Morpholinos outfitted with nucleo-base mismatches at 
five positions (5mmMO), while the inset in H depicts an atoh7 stained retina of an untreated control 
embryo. (G) Transmitted light microscopy images of untreated (up), ssbp1-splice-mismatch 
Morpholino (middle) and ssbp1-splice Morpholino (bottom) injected zebrafish embryos at 30 hpf. All 
images (A – I) are lateral views with rostral to the left. Immunofluorescences against the pan-neuronal 
marker Elavl3 (HuC) and the nerve fiber marker acetylated Tubulin (AcTub) on cross sections of eyes 
of a control- (J, n=3) and a ssbp1-splice morpholino-injected larvae at 72 hpf (K, n=4); white arrows 
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point to the optic nerve, white arrowheads to the inner plexiform layer, grey arrows to the ganglion cell 
layer and grey arrowheads to the inner nuclear layer. (L – L’’’) Statistical analysis of phenotypic 
categories as revealed by atoh7 staining after (co-)injection of ssbp1 Morpholinos and mRNAs as 
indicated. Employed categories are shown right to the chart. Statistical significance was calculated via 
a χ2-test: not injected (n=47)/plus ssbp1 5mm-ATG-MO (n=72): χ2(1)=1.3952, p=0.2375; plus ssbp1 
5mm-ATG-MO (n=72)/plus ssbp1 ATG-MO (n=44) χ2(2)=101.81, p<0.001; plus ssbp1 5mm-splice-MO 
(n=82)/plus ssbp1 splice-MO (n=52) χ2(2)=123.1, p<0.001; plus ssbp1 splice-MO (n=52)/plus ssbp1 
splice-MO and ssbp1 mRNA(wt) (n=101) χ2(2)=31.053, p<0.001; plus ssbp1 mRNA(wt) (n=39)/ plus 
ssbp1 mRNA(R38Q) (n=40) χ2(2)=32.89, p<0.001; plus ssbp1 mRNA(wt) (n=39)/plus ssbp1 
mRNA(R107Q) (n=48) χ2(2)=9.9853, p<0.006787; plus ssbp1 mRNA(wt) (n=39)/plus ssbp1 
mRNA(S141N) (n=33) χ2(2)=33.886, p<0.001; equimolar (co-)injections of ssbp1-mRNA alleles into 
morphants: plus ssbp1 mRNA(wt) (n=62)/plus ssbp1 mRNA (R107Q) (n=42): χ2(2)=68.631, p<0.001; 
plus ssbp1 mRNA(wt) (n=62)/plus ssbp1 mRNA and ssbp1 mRNA (R38Q) (n=48) χ2(2)=81.027, 
p<0.001; plus ssbp1 mRNA(wt) (n=62)/plus ssbp1 mRNA and ssbp1 mRNA (R107Q) (n=28) 
χ2(2)=46.469, p<0.001; plus ssbp1 mRNA(wt) (n=62)/plus ssbp1 mRNA and ssbp1 mRNA (S141N) 
(n=44) χ2(2)=65.648, p<0.001. Abbreviations: GCL, ganglion cell layer; INL, inner nuclear layer; IPL, 
inner plexiform layer; ns, not significant.
FIGURE 6: SSBP1 mutations of two ADOA families and two singletons.
(A) SSBP1 gene structure with seven exons (boxes). Mutations identified in Family 1 (exon 6), Family 
2 (exon 4) and two singletons of Families 3 and 4 (exons 4 and 7, respectively) are indicated above 
the exons along with Sanger sequencing chromatograms of one patient for each mutation. Open 
boxes at the beginning and the end of the gene represent untranslated regions (UTRs). (B) SSBP1 
protein domain structure (148 amino acids). Domains are indicated by the specified color code. The 
missense mutations, as inferred from the DNA variants, are indicated above the bar at the 
corresponding positions. (C) Multiple alignment of human SSBP1 homologous proteins. All mutated 
sites are strictly conserved in vertebrates. Arg38 is also conserved in insects while Arg107 is even 
conserved in insects and worms. The alignment was performed with Clustal W. Bird: Gallus gallus; 
fish: Danio rerio; frog: Xenopus laevis; insect: Drosophila melanogaster; nematode: Caenorhabditis 
briggsae. (D) Crossed-eye stereo representation of dimeric human SSBP1 X-ray structure (pdb code 
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1S3O) with the residues of basic patch B (Arg38, Lys104, Arg107 of subunit A, and pseudo-symmetry 
related Arg28 of subunit B, according to Yang et al., 1997) as well as the mutated Ser141 in stick 
representation; mutated residues in magenta, the two other basic residues in blue. Schematic 
representation of subunit A in green and subunit B in gray.
FIGURE 7: SSBP1 and OPA1 expression in mouse retina.
DAB immunohistochemistry of wax sections from 2-month-old mouse eye showing that Ssbp1 is 
abundant in the retina. OPA1 is primarily expressed in the GCL, IPL, INL, and OPL. Sections were 
counterstained with haematoxylin (blue). Panel shows a control section (primary antibody omitted). 
GC= ganglion cell layer, IPL= inner plexiform layer, INL= inner nuclear layer, OPL= outer plexiform 
layer, ONL= outer nuclear layer, PRL= photoreceptor layer, RPE= retinal pigment epithelium.
FIGURE 8: Mitochondrial staining in SH-SY5Y cells.
(A) Shows a merged fluorescence image of mitochondria labelled with mitotracker red (B) and anti-
ssbp1 (C). Arrows indicate the presence of brightly stained green punctuate structures, which may 
indicate the presence of mitochondrial nucleoids. (D) The merged image of anti-ssbp1 and anti-TFAM 
shows dots that were co-located and each dot may represent TFAM/mtDNA complex/nucleoid. 
Immunolabelling using anti-ssbp1 (E) stained in a pattern associating with the mitochondria. 
Immunolabelling using anti-TFAM (F) showed a granular pattern in the cytoplasm. Scale 25 µm for A-
C panels and 20 µm for D – F panels.
SUPPLEMENTARY
SUPPLEMENTARY TABLE 1: Clinical characterisation of affected family members.
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Abstract
Objective: Autosomal dominant optic atrophy (ADOA) starts in early childhood with loss of visual 
acuity and color vision deficits. OPA1 mutations are responsible for the majority of cases, but in a 
proportion of patients with a clinical diagnosis of ADOA, the cause remains unknown. This study 
aimed to identify novel ADOA-associated genes and explore their causality.
Methods: Linkage analysis and sequencing were performed in multi-generation families and unrelated 
patients to identify disease-causing variants. Functional consequences were investigated in silico and 
confirmed experimentally using the zebrafish model.
Results: We defined a new ADOA locus on 7q33-q35 and identified three different missense variants 
in SSBP1 (NM_001256510.1; c.113G>A (p.(Arg38Gln)), c.320G>A (p.(Arg107Gln)) and c.422G>A 
(p.(Ser141Asn))) in affected individuals from two families and two singletons with ADOA and variable 
retinal degeneration. The mutated arginine residues are part of a basic patch that is essential for 
single-strand DNA binding. The loss of a positive charge at these positions is very likely to lower the 
affinity of SSBP1 to ssDNA. Antisense-mediated knockdown of endogenous ssbp1 mRNA in zebrafish 
resulted in compromised differentiation of retinal ganglion cells. A similar effect was achieved when 
mutated mRNAs were administered. These findings point to an essential role of ssbp1 in retinal 
development and the dominant-negative nature of the identified human variants, which is consistent 
with the segregation pattern observed in two multi-generation families studied.
Interpretation: SSBP1 is an essential protein for mtDNA replication and maintenance. Our data 
established pathogenic variants in SSBP1 as a cause of ADOA and variable retinal degeneration.
Page 33 of 66
John Wiley & Sons
Annals of Neurology
For Peer Review
4
Introduction
Autosomal dominant optic atrophy (ADOA), is one of the most common inherited optic neuropathies 
seen in clinical practice with an estimated prevalence of 1 in 25,000.1 In the majority of cases, ADOA 
is caused by OPA1 gene variants, but several other genes are also known to be associated with 
isolated or syndromic forms of optic atrophy.2 However, a large number of cases remain genetically 
undiagnosed, suggesting variants in novel genes may be involved in the pathogenesis of this disorder. 
The phenotype of ADOA overlaps with Leber hereditary optic neuropathy (LHON; OMIM 535000), 
which is caused by point mutations of mitochondrial DNA (mtDNA) affecting the respiratory chain 
complexes. Hence, it was not surprising that the genes found to be associated with ADOA encode 
mitochondrial proteins. Both are mitochondrial neuropathies and show a markedly variable clinical 
phenotype. However, in most cases, the pathology seems to be limited to a highly specialised group of 
cells within the eye, the retinal ganglion cells.
Proteins of the mtDNA replication machinery are important in maintaining mitochondrial function. The 
“minimal replisome” comprises the mtDNA polymerase gamma, the helicase TWINKLE and the 
mitochondrial single-strand DNA (ssDNA) binding protein SSBP1. Variants in the genes coding for 
POLG and POLG2 as well as TWINKLE have been described to cause chronic progressive external 
ophthalmoplegia (CPEO).3 Surprisingly, no Mendelian disease has been ascribed to date to variants of 
the gene encoding SSBP1.
Here we report on the mapping of a novel locus for ADOA and the identification of heterozygous 
missense variants in SSBP1 as the underlying genetic cause in four unrelated families or single 
patients with inherited optic atrophy and subsequent retinal degeneration.
Methods
Study population and clinical investigation
Four unrelated non-consanguineous families were identified from a cohort, which was negative for 
OPA1 and the three most common LHON mutations, namely m.3460G>A (MTND1), m.11778G>A 
(MTND4) and m.14484T>C (MTND6) (Fig 1A). Written informed consent was obtained. The study had 
ethical and institutional approval (Moorfields Eye Hospital NHS Foundation Trust (REC 13/YH/0310) 
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and Cardiff & Vale University Health Board, Wales (REC 02/09/01)) and complied with the Declaration 
of Helsinki. Eleven affected individuals from three families (Family 1 (GC13572), Family 2 and Family 
3 (GC17999)), underwent full ophthalmic examination, including imaging (Fig 2) and electrophysiology 
of the visual system (Fig 3). In addition, the medical records of eight family members from three 
generations of Family 1 and the singleton from Family 4, were reviewed.
Electrophysiological investigation of Families 1 and 3 included pattern and flash visual evoked 
potential (PVEP; FVEP) and pattern and full-field electroretinography (PERG; ERG) testing, performed 
to incorporate the Standards of the International Society for Clinical Electrophysiology of Vision 
(ISCEV). An extended protocol for photopic On-Off ERG and short-wavelength flash (S-cone) ERG 
were also performed.4–7 Family 2 underwent flash VEPs and pattern reversal VEPs to a 30-minute 
check in 3 of 4 cases. Full-field ERGs (maximum DA and LA flash strength 2.25 cd.s.m-2) were 
performed in all 4 individuals; large field pattern ERGs were analysed in one. The proband of Family 4 
did not have electrophysiology assessment.
Molecular genetics
Blood samples were collected from 35 individuals (13 affected and 22 unaffected) from three 
generations of Family 1 and eight individuals (four affected and four unaffected) from two generations 
of Family 2. In parallel, individuals 4-12 of Family 1 and 2-3 of Family 3 were recruited and analyzed 
by whole-genome sequencing (WGS) as part of the 100,000 genomes project.
Linkage analysis in Family 1
In light of the clear autosomal dominant inheritance pattern of the disease in Family 1, and following 
exclusion of disease associated variants in the OPA1 gene, DNA samples were subjected to SNP 
array genotyping (Affymetrix GeneChip Human Mapping 10K Array). Linkage analysis was performed 
assuming complete penetrance and a disease allele frequency of 0.0001. Multipoint LOD scores were 
calculated using the program ALLEGRO (Fig 1B).8 Haplotypes on chromosome 7 were reconstructed 
from microsatellite genotype data (Fig 4).9
DNA enrichment and sequencing
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Enrichment of the linkage interval and subsequent sequencing were performed as described 
elsewhere.10 We used the Roche NimbleGen 385K custom sequence capture array with a capacity of 
up to 5 Mb of target sequence. The exon-based design included all exons of the protein-coding genes, 
including 100bp of flanking intron sequence and 1 kb of the promoter regions, and known miRNAs 
within the critical interval (GRCh37/hg19). Final coverage of the design was 97.9%. From the enriched 
DNA samples, we generated paired-end libraries and sequenced them on an Illumina GA IIx device 
with a read length of 2 x 36 bp.
For data handling and analysis, we used our in-house database and analysis tool kit VARBANK 2.0 
(https://varbank.ccg.uni-koeln.de/varbank2/). Reads were demultiplexed with bcl2fastq (v1.8.4) and 
aligned with bwa aln -t 4 -q 15 (v0.7.15) against the GRCh38 reference sequence.11 Duplicates were 
removed using Picard (http://broadinstitute.github.io/picard/). This was followed by local realignments 
and base quality score recalibration (GATK v3.6).12 Single nucleotide variants (SNVs) and short 
INDELs were called by combining the information obtained with three different software packages, 
namely Platypus (v0.8.1), GATK HaplotypeCaller (v3.6) and SAMtools mpileup (v1.6).12–14 For the 
assessment of variants regarding frequency and pathogenicity, we used in-house software that 
automatically queries several external databases like dbSNP (b150), gnomAD (r2.0.1) 
(http://gnomad.broadinstitute.org/), ClinVar (V2017-02-17), dbNSFP (v3.4a), ENSEMBL (b90), and 
HGMD-prof (2017-02).15–19 Moreover, we analysed 1133 exomes or Mendeliomes (TruSight™ One 
disease-associated gene panels from Illumina) of unrelated human individuals sequenced at the CCG 
to build an in-house database of variants that allowed us to filter out common technical artefacts. 
Default settings for variant filtering with the graphical user interface of VARBANK 2.0 were the 
following: read AF>25%; max gnomAD population AF<1%; in-house population AF<5%; QD>5; 
FS<40; ReadPosRankSum>-5; MQ>50; MQRankSum>-5; quorum level SNV=2; quorum level 
INDEL=1; splice site score change<-15%; TIS [translation initiation site] score change<-15%.20,21
For the validation of the mutation detected in SSBP1, co-segregation analyses in families and 
mutation screening in further patients, we performed Sanger sequencing following standard protocols.
Sanger sequencing 
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Furthermore, 31 unrelated probands (including Families 3 and 4) who underwent prior OPA1 gene 
screening and screening for three most common LHON mutations were selected for direct Sanger 
sequencing of all coding exons (including intronic splice junctions) using standard reagents and 
protocols (primers available on request). 
Interpretation of sequence variants at protein level
To study the conservation of mutated amino acid residues, we performed multiple alignments of 
SSBP1 homologous proteins using ClustalW.22 Information about the domain structure was obtained 
from UniProtKB - Q04837 (SSBP_HUMAN). To predict the consequences of the missense mutations 
in the three-dimensional space, we analyzed the structure with pdb code 1S3O, which is an 
amendment of the original dimeric human SSBP1 X-ray structure 3ULL, using the advanced program 
WebLab™ ViewerPro™ from Molecular Simulations Inc.23,24
SSBP1 and OPA1 staining of mouse retina
Whole eyes from adult mice were fixed in Davidson’s fixative for 18 hours at 4°C, dehydrated and 
cleared using a graded series of alcohol followed by xylene, and embedded in paraffin wax. Standard 
protocols for sectioning, antigen retrieval and blocking were carried out. Ssbp1 antibody (Abcam 
ab26205) and OPA1 antibody (Abcam ab 42364) were diluted in PBS+1% normal serum and 
incubated overnight at 4°C. Sections were incubated with biotinylated secondary antibody (Stratech, 
Newmarket, UK) diluted in PBS/T for 1h at room temperature, followed by ABC reagent (RTU 
Vectastain ABC reagent, PK-7100, Vector laboratories, Peterborough, UK) for 30 minutes at room 
temperature and then DAB substrate (DAB substrate kit for peroxidase SK-4100, Vector laboratories), 
and counterstained with Harris haematoxylin (Thermo Scientific). Images were acquired using a Leica 
DMRA2 microscope with QWin software. 
Cultured SH-SY5Y cells
SH-SY5Y neuroblastoma cells were cultured on coverslips in 24 well plates seeded at a density of 
5x103 cells per well and allowed to establish overnight, as per published protocols. Mitochondria were 
labelled using MitoTracker red CMXROS (Invitrogen, Paisley UK) at 100 nM for 10 minutes in full 
culture medium (50:50 MEM:Ham’s F12, 15% FBS, 2mM glutamine, 100 U penicillin / 0.1 mg/ml 
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streptomycin, NEAA)  at 37°C. Processing was as per established protocols. In addition, the cells were 
incubated with Anti-SSBP1 (ab26205, Abcam) and TFAM antibody (sc-166965, Santa Cruz), as per 
standard protocols, and stained with Hoechst 33342 (Thermofisher, UK) before mounting coverslips 
using ProLong® Gold Antifade Mountant (Thermofisher, UK) and sealing with nail polish. Images were 
acquired using a DM6000 Leica microscope (Leica, Wetzlar, Germany) with a 63X/1.4 oil Plan 
apochromat objective. 
Generation of constructs, mRNA synthesis, morpholinos and microinjection into zebrafish
A full-length cDNA clone (IRBOp991A1161D; zgc:110325) was obtained from Source Bioscience Inc 
to generate a zebrafish SSBP1 expression construct. The SSBP1 open reading frame (orf) was 
excised with EcoRI and XbaI from this EST clone and ligated into the pCS2+ expression vector.25 In 
order to eliminate an alternative start codon in the 5’-UTR of this construct, side directed mutagenesis 
was performed using the primer pair 5’-CTGGATTTTCTGGACGACATATCGGTAAAC-3’, 5’-
GTTTACCGATATGTCGTCCAGAAAATCCAG-3’. Further PCR-based site directed mutagenesis was 
applied to this source construct for th  generation of the three mutated SSBP1 versions using the 
following primers, for mutation p.(Arg38Gln): Mut1-GA-F 5’-
CAGATTCTTGGGCAAGTCGGGCAAGAC-3' and Mut1-GA-R 5’-
GTCTTGCCCGACTTGCCCAAGAATCTG-3', for mutation p.(Arg107Gln): Mut2-GA-F 5’-
GTATGTAAAGAAAGGGTCTCAGATTTTTGTGGAAGGAAAG-3' and Mut2-GA-R 5’-
CTTTCCTTCCACAAAAATCTGAGACCCTTTCTTTACATAC 3', for mutation p.(Ser141Asn): Mut3-GA-
F 5’-GATAATATTGTGTTTCTAAATGAAAACCTGCGGGACCAG-3' and Mut3-GA-R 5’-
CTGGTCCCGCAGGTTTTCATTTAGAAACACAATATTATC-3'. Sequence integrity of all generated 
SSBP1 constructs was evaluated via Sanger sequencing. Capped mRNA was prepared after plasmid 
linearization with NotI, using the mMessage mMachine Sp6 Kit (ThermoFisher).
The following antisense morpholino-oligonucleotides (MO) were obtained from Gene Tools Inc.: ATG-
MO 5’-GCGTTTCTCAACATCTCTGCTGCGT-3’, ATG-5mmMO 5’-
GCATTGCTCATCATCTGTGCTGCGA-3’, splice-MO 5’- TACTTCTTGTATTGTTACCTGTGCG-3’, 
splice-5mmMO 5’-TAGTTCTAGTATTCTTACGTGTGCA-3’. The MOs were diluted in 1xDanieu’s 
buffer to a final concentration of 0.2 pmol/nl, the mRNAs were diluted accordingly to a working 
concentration of 75pg/nl (Fig 5 L – L’’), or in the context of Fig 5 L’’’ to a concentration of 100pg/nl (wt-
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RNA single injection) or 50pg/nl each (wt- and mutant-RNA co-injections). Injections were performed 
in volumes of 1 to 1.5 nl into zebrafish embryos at the 1-2 cell stage as described. Single or co-
injections were performed as described in volumes of 1 to 1.5 nl into zebrafish embryos at the 1-2 cell 
stage as described.26,27
Immunohistochemistry, in situ hybridization and phenotype recording in zebrafish
Cryo-sectioning of 14µm slices followed by fluorescent immunohistochemistry was performed on a 
Leica Cryostat CM1850. As primary antibodies rabbit anti-Acetylated Tubulin (Cell Signaling 
Technologies, 5335T) and mouse anti-Elavl3/Huc (Thermo Fisher Scientific, A-21271) were used in 
dilutions of 1:500 in blocking medium. As secondary antibodies goat-anti-mouse AlexaFluor-488 
(ThermoFisher Scientific, A-11001) and goat-anti-rabbit AlexaFluor-555 (ThermoFisher Scientific, A-
21428) were used in dilutions of 1:1000. After mounting with Dapi inoculated Moviol, samples were 
imaged on a Zeiss LSM710 confocal microscope.
Whole-mount in situ hybridizations were performed as previously described.28 Stained specimens 
were cleared in 80% glycerol/PBS for several hours followed by mounting in 100% glycerol for image 
capturing on a Zeiss AxioImagerM.2 compound microscope using a 10x objective. Riboprobes of isl1 
and atho7 cDNA were generated and used as described.29,30 Calculation of statistical significance 
among compared groups of certain experimental conditions was done via a χ2-test utilizing the 
programming language R. To allow for χ2-testing in this context algorithmic operations were performed 
with the three sub-groups (I) strong, (II) medium, (III) weak+none (sub-groups weak and none of the 
chart in Fig 5 L – L’’’ were merged into a single phenotypic class).
Results
Clinical examination of affected individuals with SSBP1 mutation
Clinical findings are summarised in Supplementary Table 1. Where available, detailed findings are 
described below.
Family 1
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All affected individuals presented with decreased visual acuity in early childhood due to bilateral optic 
atrophy, with no additional ocular structural abnormalities. Optic atrophy was documented in isolation 
(subjects 3-16, 4-3, 4-7, 4-8 and 5-12), or before the development of retinal vessel attenuation, or 
retinal pigmentary changes (subjects 3-8, 4-12, 4-14, 4-18, 5-2 and 5-5). All examined patients had 
bilateral optic atrophy and reduction of the peripapillary retinal nerve fibre layer (RNFL) (Fig 2A and 
2B) with hypoplastic optic nerves noticed in patients 4-12 and 4-14 (Fig 2A). Retinal examination 
revealed different degrees of vessel attenuation, abnormal appearance of the fovea, and retinal 
pigmentary changes in the mid-periphery in individuals 4-12, 4-14, 4-18, 5-5 (Fig 2D and 2E). OCT 
confirmed optic atrophy and showed retinal atrophy and a thin choroid in all patients; with a focal 
disruption of photoreceptors at the fovea with intact RPE in patients 4-18, 5-5 and 5-12 (Fig 2C). In 
addition, hypothyroidism (subjects 4-12, 4-14, 4-16 and 4-18) and a renal disorder, including renal 
failure (subjects 3-8, 4-3 and 4-18), were documented. One individual (5-2) was reported to have 
nystagmus.
Family 2
Most affected members presented with decreased visual acuity in middle and late childhood, with one 
member being affected in adolescence, and one in mature adulthood (4th decade). All examined 
patients had bilateral optic atrophy, with pigment mottling in the foveal region noticed in individuals 2-
2, 2-3 and 3-4 (Fig 2D). Retinal examination did not reveal vessel attenuation and visual acuity was 
better overall compared to Family 1. The affected individuals did not have any systemic disorders.
Family 3
The proband of Family 3 was the only affected individual with bilateral optic atrophy diagnosed at the 
age of seven years. In adolescence he was noted to have retinal changes. At the age of 57 years, 
fundus examination showed bilateral optic atrophy with mild attenuation of arterioles and mild retinal 
pigment epithelium changes around the arcades (Fig 2D and 2E). OCT showed photoreceptor outer 
segment and outer nuclear layer loss with intact RPE (Fig 2C). Hypothyroidism was recorded in the 
proband and two non-affected siblings.
Family 4
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The singleton from Family 4 was diagnosed with bilateral optic atrophy in his second decade and 
subsequently examined at the age of 45 years. 
After reviewing medical records, a chronological order of ophthalmological changes were noticed: 
initially all patients presented and were diagnosed with optic atrophy, followed by retinal vessels 
attenuation and pigmentary retinal changes documented the latest (Supplementary Table 1). The 
range of follow up period was from 4 to 47 years. 
Electrophysiology
Electrophysiology findings are described below with examples (Fig 3) and a summary (Supplementary 
Table 1).
Pattern reversal VEPs were undetectable in the two oldest patients tested in Family 1 (4-12 and 4-14; 
46 and 45 years), in one younger member of Family 2 (3-4; 19 years) and showed delay and marked 
reduction in the proband of Family 3 (2-3). Other cases showed reduced pattern VEPs without delay 
(Family 1: 5-2), had an abnormal bifid or broad waveform (Family 1: 5-5 and Family 2: 2-2) or a 
delayed major positive peak (Family 1: 5-12 and 2-3). Flash VEPs were undetectable in two cases 
(Family 1: 4-14 and Family2: 3-4). Pattern ERGs were undetectable in the 2 oldest patients of Family 
1, suggesting macular dysfunction, and were not recordable due to nystagmus in one other case 
(Family 1: 5-2). PERG N95:P50 ratio was subnormal in four cases (Family 1: 5-5, 5-12 and 3-4, and 
Family 3: 2-3) and P50 was additionally of abnormal short peak time in two (Family 1: 5-5 and 5-12) 
and, with additional mildly reduction in Family 1: 5-5. 
Full-field ERGs were abnormal in four of five affected individuals in Family 1 and in the proband of 
Family 3, consistent with generalised rod and cone photoreceptor dysfunction, most severe in case 4-
14, and affecting rods slightly more than cones in the four with milder ERG abnormalities (Family 1: 4-
12, 5-2, 5-5 and Family 3: 2-3). On-Off ERG b-waves were delayed in two cases with relative 
preservation of d-waves, analysable in 3 of 3. The flash ERGs in the youngest patient of Family 1 and 
in 4 of 4 in Family 2 revealed no abnormality.
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The VEPs and PERG obtained in Family 1: 5-5 at the age of 18 years, were reasonably stable when 
repeated at the age of 26 years, but full-field ERGs showed evidence of worsening rod and cone 
system function.
In summary, there was PERG and VEP evidence of optic nerve/retinal ganglion cell dysfunction in four 
cases without macular cone dysfunction (Family 1: 5-5, 5-12, 3-4 and Family 3: 2-3); severe flash VEP 
and/or pattern VEP abnormalities suggesting optic nerve dysfunction in 4-14 (Family 1) and likely 4-12 
(Family 1), but with PERG evidence of additional macular dysfunction in both, and in case 5-2 (Family 
1), an abnormal PVEP that may have related to optic nerve dysfunction and/or nystagmus. The ERGs 
in Families 1 and 3 indicated additional generalised photoreceptor involvement in all but the youngest 
individual, with evidence of severe photoreceptor (N=1) or rod-cone dystrophy (N=4). In one individual 
monitored over eight years (Family 1: 5-5), optic nerve/retinal ganglion cell dysfunction was stable, but 
there was ERG evidence of a mildly progressive rod-cone dystrophy. 
Mapping of a new locus for ADOA in Family 1
Among our patients without mutations in genes known to be associated with optic atrophy, we 
ascertained a large family with 23 affected individuals in five generations displaying an autosomal 
dominant mode of inheritance (Fig 1A). Genome-wide linkage analysis using 10K SNP array genotype 
data of 13 individuals (boxed IDs) established a new disease-associated locus on the long arm of 
chromosome 7 based on a significant LOD score of 3.61 (Fig 1B). We then performed fine-mapping 
using microsatellite markers from the linkage region. A haplotype analysis of the extended pedigree 
revealed recombined disease haplotypes in individuals 4-3 and 4-18, defining a critical interval of ~9.5 
Mb between the Marshfield marker GATA30F12 and D7S3044 (Fig 4). A partial re-analysis of the 
family using high-density SNP arrays (Illumina 317 K BeadChip) slightly reduced this interval with the 
final flanking markers being rs7800258 (GRCh37 (hg19) chr7:135,836,989) and rs10280300 (GRCh37 
(hg19) chr7:145,209,049).
Identification of mutations in SSBP1
To identify the underlying gene variant in Family 1, we enriched all protein-coding genes (>100) and 
known miRNAs within the critical interval by using Roche NimbleGen’s 385K custom sequence 
capture array. DNA of the two recombinant affected females 4-3 and 4-18 from Family 1 was 
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subjected to target enrichment and sequencing. Enrichment factors of 206-fold and 567-fold were 
achieved for 4-3 and 4-18, respectively, as determined by quantitative PCR of four control loci at the 
array in a comparison of enriched versus non-enriched DNA. The two libraries were subjected to 
massively parallel sequencing (Illumina GA IIx), resulting in approximately 2,828.6 Mb and 2,606.0 Mb 
of mapped sequences for the two individuals analyzed. The average coverage of the 671,414 bp of 
target sequences was higher than 270x in both samples. Called variants were filtered using the latest 
version of VARBANK’s graphical user interface (https://varbank.ccg.uni-koeln.de/varbank2) with 
default parameters set to focus on rare high-quality variants altering the protein sequence or showing 
impairments of splice and translation initiation sites. This resulted in a single variant that was identical 
in both samples, namely a heterozygous missense mutation in SSBP1 (NM_001256510.1; c.320G>A 
(p(.Arg107Gln)). Pathogenicity rank scores from 31 algorithms, (including CADD, DANN, Eigen, 
FATHMM, fitCons, GenoCanyon, Gerp, LRT, M-CAP, MetaLR, MetaSVM, MutationAssessor, 
MutationTaster, MutPred, phastCons, phyloP, Polyphen2, PROVEAN, REVEL, RF, SIFT, SiPhy, 
VEST3) were taken from the dbNSFP v.3.4a database.17 Rank scores are always in the range 
between 0 and 1 and the meaning of a rank score of 0.9 indicates that it is more likely for the SNV to 
be damaging then 90% of all potential non-synonymous SNVs. The median of all 31 rank scores for 
this variant was 0.75. 
Subsequent Sanger sequencing of 31 unrelated OPA1 and mtDNA negative patients revealed three 
further individuals with a variant in SSBP1. In 2 patients, we identified the variant c.113G>A 
(p.(Arg38Gln)) (Families 2 and 3) and in the third (Family 4), the variant c.422G>A (p.(Ser141Asn)) 
(Fig 6A). The variants cosegregated perfectly with disease in all available individuals of Families 1 and 
2. All variants are absent from the gnomAD dataset (comprising over 240,000 alleles).
As part of the 100,000 genomes project, individuals 4-12 of Family 1 and 2-3 of Family 3 were 
analyzed by whole-genome sequencing as described previously.31 To confirm the SSBP1 variants to 
be the most likely disease-associated variants in these individuals, we first excluded all candidate 
variants occurring in a virtual panel of genes previously shown to be associated with posterior 
segment disorders or inherited optic neuropathies 
(https://panelapp.genomicsengland.co.uk/panels/186/ and 
https://panelapp.genomicsengland.co.uk/panels/307/) and all known mtDNA mutations. Subsequent 
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analysis on the genomic region defined by the linkage interval in Family 1, confirmed the previously 
identified SSBP1 variant as the most likely disease-causing variant. 
SSBP1 encodes a single-stranded DNA binding protein which is essential for mtDNA replication and 
maintenance.32 All variants are located in the functionally relevant single strand DNA binding domain 
of SSBP1 and affect sites that are strictly conserved in vertebrates (Fig 6B and 6C). Notably, residues 
Arg38 and Arg107 are each part of the basic patch B consisting of four basic amino acid side chains 
important in supporting the protein/ssDNA interaction. Loss of a positive charge here may decrease 
the ssDNA affinity at a substantial degree.24 The serine at position 141 is the last residue of a ß-
extended strand located nearby at the flexible C-terminus of the protein (Fig 6D) where mutation to 
asparagine may disturb tetramer formation. 
PCR-free WGS preserves the dosage of the genome enabling detection of copy loss and gain. In 
addition, the complete coverage of >95% of the genome including the full mtDNA by 150bp paired end 
reads enables the accurate characterization of structural variant breakpoints.33 Therefore, by 
interrogating mtDNA read depth and split/chimeric read data we were not able to demonstrate any 
evidence of accumulations of large or small mtDNA deletions in the WGS data of individuals from the 
family 1 and family 3 (data not shown). This was consistent with long-range PCR studies of blood DNA 
from 3 affected individuals (5-5 and 5-12 of family 1 and 2-3 of family 3) with no evidence of mtDNA 
deletions in the blood DNA samples.
SSBP1 expression in mouse and zebrafish and consequences of ssbp1 knock-down and 
forced expression of its mutant variants on zebrafish development
To demonstrate the expression of SSBP1 in the eye, we performed DAB immunohistochemistry and 
confirmed that SSBP1 is abundant in all the layers of the retina (Fig 7). Furthermore, we found it co-
localised with mitochondria and mitochondrial nucleoids in SH-SY5Y cells labelled with mitotracker 
(Fig 8B) and anti-TFAM (Fig 8F). To study whether the role of SSBP1 in supporting retinal development 
and/or maintenance is evolutionary conserved, we knocked it down in zebrafish, a widely used 
vertebrate model system for biomedical research, including mitochondrial biology and 
neurodegeneration.34 During development, zebrafish ssbp1 is ubiquitously expressed, including the 
retina, as formerly revealed via whole mount in situ hybridizations of embryos up to five days post 
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fertilization (which corresponds to birth in mammals) (https://zfin.org/ZDB-PUB-040907-1). Injection of 
fertilized zebrafish eggs with two different antisense morpholino oligonucleotides to block the 
translation or splicing of endogenous ssbp1 mRNA resulted in strongly reduced expression of the 
developmental regulator genes isl1 and atoh7 in RGC precursors, while other expression domains of 
isl1 in the developing brain (Fig 5A-F) and overall embryo morphology (Fig 5G) were normal.35 Later, 
non-photoreceptor cells both in the ganglion cell layer (GCL) and, most likely secondarily, in the inner 
nuclear layer (INL) displayed compromised neuronal specification, while cell numbers in both layers 
were unaltered (Fig 5J,K). Furthermore, the optic nerve, consisting of RGC axons, was much thinner 
(Fig 5J,K), consistent with the axonal deficiencies of peripheral neurons formerly reported for zebrafish 
ssbp3 morphants.36–38 In contrast, the respective 5-mismatch ssbp1 morpholino controls had no 
effects (Fig 5J,L,L’), while re-introduction of ssbp1 mRNA via co-injection with the ssbp1 splice 
morpholino led to a significant alleviation of the retinal defects (Fig 5L’). These alterations clearly affect 
the initial specification, rather than the later maintenance of RGCs, as seen in human patients (see 
also Discussion). However, both result in similar RGC and optic nerve defects, suggesting that the 
identified human missense mutations have loss of SSBP1 function effects.
Dominantly inherited loss-of-function mutations as in the case of the human patients could either be 
due to haploinsufficiency or dominant negative (antimorphic) effects. In order to distinguish between 
these two possibilities, we again employed the zebrafish system to study the effects of the 
corresponding mutant ssbp1 mRNAs when exogenously applied.  Strikingly, all tested mutant versions 
(p.(Arg38Gln), p.(Arg107Gln) and p.(Ser141Asn)) caused a reduction in retinal atoh7 expression, both 
when administered singly to compete with the endogenous wild-type Ssbp1, and when administered 
together with equimolar amounts of exogeneous wild-type ssbp1 mRNA into ssbp1 morphants (Fig 
5H,I,L’’,L’’’), suggesting that the mutant versions have a dominant negative effect on wild-type Ssbp1. 
Discussion
Heterozygous missense variants in the SSBP1 were identified in patients with a form of bilateral optic 
neuropathy, commonly associated with additional and subsequent variable pigmentary retinal 
changes. This is the first report of Mendelian disease caused by variants in SSBP1 and highlights the 
link between SSBP1 dysfunction and mitochondrial-related optic neuropathy.
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Although optic neuropathy is a prominent ophthalmological feature of mitochondrial diseases, it is not 
universal and phenotypic variation, such as retinal degeneration with pigmentary retinal changes or 
chronic progressive ophthalmoplegia, can be seen in patients with mitochondrial disorders. Retinal 
degeneration can be accompanied by vascular attenuation, which becomes more noticeable with 
disease progression and increasing patient age.39 Pigmentary changes can be seen in CPEO, 
specifically in Kearns-Sayre syndrome.40 However these changes can also be detected among 
patients with MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like 
episodes), MIDD (maternally inherited diabetes and deafness), MNGIE (mitochondrial 
neurogastrointestinal encephalomyopathy), OPA1 mutations, MILS (maternally inherited Leigh 
syndrome) and NARP (neuropathy, ataxia and retinitis pigmentosa).41 Recently, optic atrophy with 
vessel attenuation and retinal degeneration has been reported in a patient found to harbour ACO2 
mutation.42 A similar phenotype of both optic atrophy and pigmentary retinal changes was a common 
feature in the current study. In some of the cases reported here the retinal changes was very mild, as 
in the younger members of Family 1 and Family 3, detected only on detailed fundus examination or 
retinal imaging, and on ERG testing. However, in Family 1 optic atrophy and pigmentary retinal 
changes were prominent features; but absent in Family 2. The link between mitochondrial dysfunction 
and retinal degeneration may relate to the production of reactive oxygen species (ROS), which is a 
normal metabolic process during the phagocytosis of photoreceptor outer segments in the retina. If 
mitochondrial function is impaired, the retinal pigment epithelium (RPE) may be exposed to higher 
levels of ROS, leading to cumulative oxidative damage to the RPE and subsequently manifesting as 
pigmentary retinopathy.
In addition to the optic neuropathy and retinal degeneration some affected individuals in Family 1 and 
Family 3 were diagnosed with renal disease and hypothyroidism although at least one unaffected non-
carrier of the variant was also reported to also have hypothyroidism. Other studies are necessary to 
explore the relationship between SSBP1 variants and additional systemic disease features. 
Furthermore, as we could not perform segregation analysis in singleton case from Family 4, we 
assume that identified variant is causal. By analysing WGS data and long-range PCR studies on blood 
DNA of affected individuals from two families, we ruled out the accumulation of large-scale mtDNA 
rearrangements, in particular mtDNA deletions. However, we did not have access to skeletal muscle 
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tissue to further study whether SSBP1 mutations results in mtDNA instability and the link with the 
underlying disease pathophysiology.
In surveying our current knowledge of the biochemical components of the mtDNA replication 
machinery, it is striking that mutations in POLG/POLG2 and TWNK lead to progressive 
ophthalmoplegia while mutations in SSBP1 cause a different phenotype.43 All four gene products form 
together on the replication machinery therefore one might expect highly overlapping phenotypes. It 
may be that the role of SSBP1 is more cell-type specific.
SSBP1 is essential for mtDNA replication and maintenance, its downregulation or dysfunction may be 
expected to affect mtDNA copy number, resulting in mitochondrial morphological and functional 
changes, including accumulation of reactive oxygen species in mitochondria. 44 It is likely that biallelic 
loss of gene function (knock out) would be incompatible with life 
(http://www.mousephenotype.org/data/genes/MGI:1920040). However, the ExAC and gnomAD 
datasets include heterozygous carriers of predicted LOF variants and a probability of loss of function 
intolerance score (pLI) of 0.00 (gnomAD) for SSBP1 suggesting that haploinsufficiency is unlikely to 
be associated with paediatric onset Mendelian disease.45 In addition, recently, it was reported that a 
heterozygous start loss variant in the SSBP1 co-segregated with sensorineural hearing loss in a large 
family harbouring the variable penetrance m.1555A>G maternally inherited deafness variant. The 
authors stated that SSBP1 variant leads to reduced SSBP1 level and perturbation of mtDNA 
metabolism, but the presence of an SSBP1 start loss mutation alone was not associated with disease 
unless in conjunction with the m.1555A>G variant.46
The variants reported herein are missense changes that affect amino acid residues in close proximity 
in the SSBP1 tertiary structure. Two of them are likely to weaken the interaction with ssDNA as they 
partially disrupt a basic patch, through which ssDNA binding is accomplished. For p.(Ser141Asn) we 
propose an interference with tetramer formation as the most likely consequence as it was shown that 
substitution of that serine by cysteine results in a covalent linkage of the dimers within the tetramer.24 
Thus the Ser141 is exposed and obviously situated in a region of the structure involved in dimer 
contacts underlying the tetramer formation. In addition p.(Arg38Gln) is found in two not knowingly 
related families suggesting it may be a recurrent mutation representing a hotspot for mutation. 
Therefore, we hypothesise that these variants in SSBP1 act as dominant-negative variants which is 
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further supported by our functional analyses performed in zebrafish embryos. Here, both antisense-
mediated inactivation of the endogenous ssbp1 mRNA as well as administration of exogenous mRNAs 
carrying the identified human mutations led to compromised development of RGCs, pointing to an 
essential role of SSBP1 in retina development and a dominant-negative nature of the human 
mutations, in line with their dominant inheritance. Unfortunately, due to the temporal restriction of 
morpholino-based ssbp1 knockdown in zebrafish (being only effective for approximately 3 days after 
administration), and the pre-weaning lethality of homozygous Ssbp1 null mutants in the mouse 
(http://www.mousephenotype.org/data/genes/MGI:1920040), we could not investigate possible later 
retinal degeneration in these animal models. However, the combination of early RGC specification 
defects in zebrafish and later RGC degeneration in human is nicely in line with the concept of shared 
genetic control of early specification and later maintenance of neurons, as not only reported in the 
context of retinal development and degeneration, but also for dopaminergic neurons and Parkinson’s 
disease.47–49
To summarise, we report detailed genetic, clinical and electrophysiological features in similarly 
affected individuals from four families with early onset bilateral optic neuropathy and subsequent 
retinal degeneration. This study identifies missense variants affecting highly conserved amino acid 
residues in the ssDNA binding domain of SSBP1 and their association with disease.
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Figure legends
FIGURE 1: Mapping of a new ADOA locus.
(A) Pedigrees of four families with ADOA of previously unknown underlying genetic cause. An asterisk 
indicates family members from whom DNA was available. (B) Schematic representation of genome-
wide LOD score calculations after 10K array SNP genotyping of 13 samples from family 1 (boxed ID 
numbers). LOD scores calculated with ALLEGRO are given along the y-axis relative to genomic 
position in cM (centi Morgan) on the x-axis. Note the highest peak (LOD = 3.61) in a region on 
chromosome 7.
FIGURE 2: Colour optic nerve head, fundus, fundus autofluorescence (FAF) and OCT composite of 
affected members (single eye selected).
(A) Colour image of the optic nerve head shows different degrees of optic atrophy. (B, F) OCT B-scan 
of the disc (top) and circumpapillary area (bottom) showing atrophic optic nerve head and RNFL 
thinning; (C, F) OCT scans through macula showing thin atrophic retina with focal loss of the outer 
retina. (D) Fundus colour photographs from the affected family members:  various degrees attenuated 
vessels and pigmentary changes in Family 1: 4-12, 4-14, 4-18, 5-5 Family 2: 2-2, 2-3 and singleton 
case of Family 3 (E) FAF of the patient 4-12 (F1) showing an area of decreased autofluorescence 
around the vessels arcades more prominent on the superior part. 4-14 (F1) FAF shows patches of 
hypoautofluorescence including atrophic areas in posterior pole with hyperautofluorescence area next 
to optic disc. 4-18 (F1) FAF indicates an increased autofluorescence in fovea. FAF of 5-5 (F1) shows 
hypofluorescent patchy pattern in midperipheral retina and increased autofluorescence in the fovea. 5-
12 (F1) normal FAF. 2-3 (F3) diffuse hyperautofluorescence in posterior pole with 
hypoautofluorescence around the vessels arcades and in fovea.
FIGURE 3: Pattern ERG (PERG) and pattern reversal and flash VEP (PVEP; FVEP) recordings for the 
right eyes of 6 affected individuals, including 8 years after baseline testing in case 5-5 of Family 1.
All recordings showed a high degree of inter-ocular symmetry. The age of each individual at the time 
of recording is indicated. All waveforms are superimposed to demonstrate reproducibility. It was not 
possible to obtain a PERG recording in case 5-2 due the effects of eye movements. Recordings from a 
representative control subject are shown for comparison (control). PERG is undetectable (4-12 and 4-
14), shows a P50 component of short peak time (5-5 and 5-12) and a reduced N95:P50 ratio (5-5, 5-
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12 and Family 3 2-3). PVEPs are abnormal in all cases and FVEPs undetectable in one (4-14). See 
text for details. Full-field ERGs from the right eyes in each of 6 cases that underwent International 
standard ERG testing, with additional On-Off and S-cone ERGs, and representative control recordings 
from a healthy subject for comparison (control). Dark-adapted (DA) ERGs are shown for white flashes 
of 0.01, and 10.0 cd.s.m-2. Light-adapted (LA) ERGs are shown for white flashes of 3.0 cd.s.m-2 (30Hz 
and 2Hz). Traces are superimposed to demonstrate reproducibility (with exception of On-Off ERG in 5-
2). Broken lines replace blink artefacts that occur soon after b-waves in DA10 ERGs and in the On-Off 
ERGs in Family 3 2-3.  All 5 cases show evidence of generalised retinal dysfunction with either similar 
severity of rod and cone involvement (4-14) or rod-cone dystrophy (4-12; 5-2; 5-5, Family 3 2-3). 
There is evidence of progression in 5-5 between the ages of 18 and 26 years.
FIGURE 4: Identification of recombination breakpoints in family 1.
Reconstruction of haplotypes was performed using genotype information of 14 STR markers from the 
linkage region on chromosome 7q33-q35. The disease haplotype is shown in red. Recombination 
events are visible in individuals 4-3 and 4-18 (boxed marker alleles). They define a ~9.5 Mb critical 
interval for the disease locus. The flanking markers are GATA30F12 and D7S3044 at the proximal and 
distal end, respectively. Markers within the critical interval are printed in bold type.
FIGURE 5: Knock-down of ssbp1 as well as expression of mutant ssbp1 versions result in impaired 
initiation of retinal ganglion cell (RGC) differentiation and retinal integrity in zebrafish.
Expression of the RGC markers Isl1 (A-C) and atho7 (D-F, H, I) was visualized by whole-mount RNA 
in situ hybridization in eyes of zebrafish embryos injected with either antisense Morpholino-
oligonucleotides against ssbp1 (B, C, E, F) or with mRNA of distinct ssbp1 alleles (H, I) as indicated at 
30 hours post fertilization (hpf). Arrows in A to C point at isl1 positive RGCs.  Insets in E and F show 
retinas of embryos injected with cognate control Morpholinos outfitted with nucleo-base mismatches at 
five positions (5mmMO), while the inset in H depicts an atoh7 stained retina of an untreated control 
embryo. (G) Transmitted light microscopy images of untreated (up), ssbp1-splice-mismatch 
Morpholino (middle) and ssbp1-splice Morpholino (bottom) injected zebrafish embryos at 30 hpf. All 
images (A – I) are lateral views with rostral to the left. Immunofluorescences against the pan-neuronal 
marker Elavl3 (HuC) and the nerve fiber marker acetylated Tubulin (AcTub) on cross sections of eyes 
of a control- (J, n=3) and a ssbp1-splice morpholino-injected larvae at 72 hpf (K, n=4); white arrows 
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point to the optic nerve, white arrowheads to the inner plexiform layer, grey arrows to the ganglion cell 
layer and grey arrowheads to the inner nuclear layer. (L – L’’’) Statistical analysis of phenotypic 
categories as revealed by atoh7 staining after (co-)injection of ssbp1 Morpholinos and mRNAs as 
indicated. Employed categories are shown right to the chart. Statistical significance was calculated via 
a χ2-test: not injected (n=47)/plus ssbp1 5mm-ATG-MO (n=72): χ2(1)=1.3952, p=0.2375; plus ssbp1 
5mm-ATG-MO (n=72)/plus ssbp1 ATG-MO (n=44) χ2(2)=101.81, p<0.001; plus ssbp1 5mm-splice-MO 
(n=82)/plus ssbp1 splice-MO (n=52) χ2(2)=123.1, p<0.001; plus ssbp1 splice-MO (n=52)/plus ssbp1 
splice-MO and ssbp1 mRNA(wt) (n=101) χ2(2)=31.053, p<0.001; plus ssbp1 mRNA(wt) (n=39)/ plus 
ssbp1 mRNA(R38Q) (n=40) χ2(2)=32.89, p<0.001; plus ssbp1 mRNA(wt) (n=39)/plus ssbp1 
mRNA(R107Q) (n=48) χ2(2)=9.9853, p<0.006787; plus ssbp1 mRNA(wt) (n=39)/plus ssbp1 
mRNA(S141N) (n=33) χ2(2)=33.886, p<0.001; equimolar (co-)injections of ssbp1-mRNA alleles into 
morphants: plus ssbp1 mRNA(wt) (n=62)/plus ssbp1 mRNA (R107Q) (n=42): χ2(2)=68.631, p<0.001; 
plus ssbp1 mRNA(wt) (n=62)/plus ssbp1 mRNA and ssbp1 mRNA (R38Q) (n=48) χ2(2)=81.027, 
p<0.001; plus ssbp1 mRNA(wt) (n=62)/plus ssbp1 mRNA and ssbp1 mRNA (R107Q) (n=28) 
χ2(2)=46.469, p<0.001; plus ssbp1 mRNA(wt) (n=62)/plus ssbp1 mRNA and ssbp1 mRNA (S141N) 
(n=44) χ2(2)=65.648, p<0.001. Abbreviations: GCL, ganglion cell layer; INL, inner nuclear layer; IPL, 
inner plexiform layer; ns, not significant.
FIGURE 6: SSBP1 mutations of two ADOA families and two singletons.
(A) SSBP1 gene structure with seven exons (boxes). Mutations identified in Family 1 (exon 6), Family 
2 (exon 4) and two singletons of Families 3 and 4 (exons 4 and 7, respectively) are indicated above 
the exons along with Sanger sequencing chromatograms of one patient for each mutation. Open 
boxes at the beginning and the end of the gene represent untranslated regions (UTRs). (B) SSBP1 
protein domain structure (148 amino acids). Domains are indicated by the specified color code. The 
missense mutations, as inferred from the DNA variants, are indicated above the bar at the 
corresponding positions. (C) Multiple alignment of human SSBP1 homologous proteins. All mutated 
sites are strictly conserved in vertebrates. Arg38 is also conserved in insects while Arg107 is even 
conserved in insects and worms. The alignment was performed with Clustal W. Bird: Gallus gallus; 
fish: Danio rerio; frog: Xenopus laevis; insect: Drosophila melanogaster; nematode: Caenorhabditis 
briggsae. (D) Crossed-eye stereo representation of dimeric human SSBP1 X-ray structure (pdb code 
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1S3O) with the residues of basic patch B (Arg38, Lys104, Arg107 of subunit A, and pseudo-symmetry 
related Arg28 of subunit B, according to Yang et al., 1997) as well as the mutated Ser141 in stick 
representation; mutated residues in magenta, the two other basic residues in blue. Schematic 
representation of subunit A in green and subunit B in gray.
FIGURE 7: SSBP1 and OPA1 expression in mouse retina.
DAB immunohistochemistry of wax sections from 2-month-old mouse eye showing that Ssbp1 is 
abundant in the retina. OPA1 is primarily expressed in the GCL, IPL, INL, and OPL. Sections were 
counterstained with haematoxylin (blue). Panel shows a control section (primary antibody omitted). 
GC= ganglion cell layer, IPL= inner plexiform layer, INL= inner nuclear layer, OPL= outer plexiform 
layer, ONL= outer nuclear layer, PRL= photoreceptor layer, RPE= retinal pigment epithelium.
FIGURE 8: Mitochondrial staining in SH-SY5Y cells.
(A) Shows a merged fluorescence image of mitochondria labelled with mitotracker red (B) and anti-
ssbp1 (C). Arrows indicate the presence of brightly stained green punctuate structures, which may 
indicate the presence of mitochondrial nucleoids. (D) The merged image of anti-ssbp1 and anti-TFAM shows dots 
that were co-located and each dot may represent TFAM/mtDNA complex/nucleoid. Immunolabelling using anti-ssbp1 (E) 
stained in a pattern associating with the mitochondria. Immunolabelling using anti-TFAM (F) showed a granular pattern in 
the cytoplasm.
SUPPLEMENTARY
SUPPLEMENTARY TABLE 1: Clinical characterisation of affected family members.
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FIGURE 1: Mapping of a new ADOA locus.%"(A) Pedigrees of four families with ADOA of previously unknown 
underlying genetic cause. An asterisk indicates family members from whom DNA was available. (B) 
Schematic representation of genome-wide LOD score calculations after 10K array SNP genotyping of 13 
samples from family 1 (boxed ID numbers). LOD scores calculated with ALLEGRO are given along the y-axis 
relative to genomic position in cM (centi Morgan) on the x-axis. Note the highest peak (LOD = 3.61) in a 
region on chromosome 7. 
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FIGURE 2: Colour optic nerve head, fundus, fundus autofluorescence (FAF) and OCT composite of affected 
members (single eye selected)."(A) Colour image of the optic nerve head shows different degrees of optic 
atrophy. (B, F) OCT B-scan of the disc (top) and circumpapillary area (bottom) showing atrophic optic nerve 
head and RNFL thinning; (C, F) OCT scans through macula showing thin atrophic retina with focal loss of the 
outer retina. (D) Fundus colour photographs from the affected family members:  various degrees attenuated 
vessels and pigmentary changes in Family 1: 4-12, 4-14, 4-18, 5-5 Family 2: 2-2, 2-3 and singleton case of 
Family 3 (E) FAF of the patient 4-12 (F1) showing an area of decreased autofluorescence around the vessels 
arcades more prominent on the superior part. 4-14 (F1) FAF shows patches of hypoautofluorescence 
including atrophic areas in posterior pole with hyperautofluorescence area next to optic disc. 4-18 (F1) FAF 
indicates an increased autofluorescence in fovea. FAF of 5-5 (F1) shows hypofluorescent patchy pattern in 
midperipheral retina and increased autofluorescence in the fovea. 5-12 (F1) normal FAF. 2-3 (F3) diffuse 
hyperautofluorescence in posterior pole with hypoautofluorescence around the vessels arcades and in fovea. 
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FIGURE 3: Pattern ERG (PERG) and pattern reversal and flash VEP (PVEP; FVEP) recordings for the right 
eyes of 6 affected individuals, including 8 years after baseline testing in case 5-5 of Family 1.All recordings 
showed a high degree of inter-ocular symmetry. The age of each individual at the time of recording is 
indicated. All waveforms are superimposed to demonstrate reproducibility. It was not possible to obtain a 
PERG recording in case 5-2 due the effects of eye movements. Recordings from a representative control 
subject are shown for comparison (control). PERG is undetectable (4-12 and 4-14), shows a P50 component 
of short peak time (5-5 and 5-12) and a reduced N95:P50 ratio (5-5, 5-12 and Family 3 2-3). PVEPs are 
abnormal in all cases and FVEPs undetectable in one (4-14). See text for details. Full-field ERGs from the 
right eyes in each of 6 cases that underwent International standard ERG testing, with additional On-Off and 
S-cone ERGs, and representative control recordings from a healthy subject for comparison (control). Dark-
adapted (DA) ERGs are shown for white flashes of 0.01, and 10.0 cd.s.m-2. Light-adapted (LA) ERGs are 
shown for white flashes of 3.0 cd.s.m-2 (30Hz and 2Hz). Traces are superimposed to demonstrate 
reproducibility (with exception of On-Off ERG in 5-2). Broken lines replace blink artefacts that occur soon 
after b-waves in DA10 ERGs and in the On-Off ERGs in Family 3 2-3.  All 5 cases show evidence of 
generalised retinal dysfunction with either similar severity of rod and cone involvement (4-14) or rod-cone 
dystrophy (4-12; 5-2; 5-5, Family 3 2-3). There is evidence of progression in 5-5 between the ages of 18 
and 26 years. 
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FIGURE 4: Identification of recombination breakpoints in family 1. 
Reconstruction of haplotypes was performed using genotype information of 14 STR markers from the linkage 
region on chromosome 7q33-q35. The disease haplotype is shown in red. Recombination events are visible 
in individuals 4-3 and 4-18 (boxed marker alleles). They define a ~9.5 Mb critical interval for the disease 
locus. The flanking markers are GATA30F12 and D7S3044 at the proximal and distal end, respectively. 
Markers within the critical interval are printed in bold type. 
175x135mm (300 x 300 DPI) 
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FIGURE 5: Knock-down of ssbp1 as well as expression of mutant ssbp1 versions result in impaired initiation 
of retinal ganglion cell (RGC) differentiation and retinal integrity in zebrafish. 
Expression of the RGC markers Isl1 (A-C) and atho7 (D-F, H, I) was visualized by whole-mount RNA in situ 
hybridization in eyes of zebrafish embryos injected with either antisense Morpholino-oligonucleotides against 
ssbp1 (B, C, E, F) or with mRNA of distinct ssbp1 alleles (H, I) as indicated at 30 hours post fertilization 
(hpf). Arrows in A to C point at isl1 positive RGCs.  Insets in E and F show retinas of embryos injected with 
cognate control Morpholinos outfitted with nucleo-base mismatches at five positions (5mmMO), while the 
inset in H depicts an atoh7 stained retina of an untreated control embryo. (G) Transmitted light microscopy 
images of untreated (up), ssbp1-splice-mismatch Morpholino (middle) and ssbp1-splice Morpholino (bottom) 
injected zebrafish embryos at 30 hpf. All images (A – I) are lateral views with rostral to the left. 
Immunofluorescences against the pan-neuronal marker Elavl3 (HuC) and the nerve fiber marker acetylated 
Tubulin (AcTub) on cross sections of eyes of a control- (J, n=3) and a ssbp1-splice morpholino-injected 
larvae at 72 hpf (K, n=4); white arrows point to the optic nerve, white arrowheads to the inner plexiform 
layer, grey arrows to the ganglion cell layer and grey arrowheads to the inner nuclear layer. (L – L’’’) 
Statistical analysis of phenotypic categories as revealed by atoh7 staining after (co-)injection of ssbp1 
Morpholinos and mRNAs as indicated. Employed categories are shown right to the chart. Statistical 
significance was calculated via a  2-test: not injected (n=47)/plus ssbp1 5mm-ATG-MO (n=72): 
 2(1)=1.3952, p=0.2375; plus ssbp1 5mm-ATG-MO (n=72)/plus ssbp1 ATG-MO (n=44)  2(2)=101.81, 
p<0.001; plus ssbp1 5mm-splice-MO (n=82)/plus ssbp1 splice-MO (n=52)  2(2)=123.1, p<0.001; plus 
ssbp1 splice-MO (n=52)/plus ssbp1 splice-MO and ssbp1 mRNA(wt) (n=101)  2(2)=31.053, p<0.001; plus 
ssbp1 mRNA(wt) (n=39)/ plus ssbp1 mRNA(R38Q) (n=40)  2(2)=32.89, p<0.001; plus ssbp1 mRNA(wt) 
(n=39)/plus ssbp1 mRNA(R107Q) (n=48)  2(2)=9.9853, p<0.006787; plus ssbp1 mRNA(wt) (n=39)/plus 
ssbp1 mRNA(S141N) (n=33)  2(2)=33.886, p<0.001; equimolar (co-)injections of ssbp1-mRNA alleles into 
Page 63 of 66
John Wiley & Sons
Annals of Neurology
For Peer Review
morphants: plus ssbp1 mRNA(wt) (n=62)/plus ssbp1 mRNA (R107Q) (n=42):  2(2)=68.631, p<0.001; 
plus ssbp1 mRNA(wt) (n=62)/plus ssbp1 mRNA and ssbp1 mRNA (R38Q) (n=48)  2(2)=81.027, p<0.001; 
plus ssbp1 mRNA(wt) (n=62)/plus ssbp1 mRNA and ssbp1 mRNA (R107Q) (n=28)  2(2)=46.469, 
p<0.001; plus ssbp1 mRNA(wt) (n=62)/plus ssbp1 mRNA and ssbp1 mRNA (S141N) (n=44)  2(2)=65.648, 
p<0.001. Abbreviations: GCL, ganglion cell layer; INL, inner nuclear layer; IPL, inner plexiform layer; ns, 
not significant. 
Page 64 of 66
John Wiley & Sons
Annals of Neurology
For Peer Review
 
FIGURE 6: SSBP1 mutations of two ADOA families and two singletons. 
(A) SSBP1 gene structure with seven exons (boxes). Mutations identified in Family 1 (exon 6), Family 2 
(exon 4) and two singletons of Families 3 and 4 (exons 4 and 7, respectively) are indicated above the exons 
along with Sanger sequencing chromatograms of one patient for each mutation. Open boxes at the 
beginning and the end of the gene represent untranslated regions (UTRs). (B) SSBP1 protein domain 
structure (148 amino acids). Domains are indicated by the specified color code. The missense mutations, as 
inferred from the DNA variants, are indicated above the bar at the corresponding positions. (C) Multiple 
alignment of human SSBP1 homologous proteins. All mutated sites are strictly conserved in vertebrates. 
Arg38 is also conserved in insects while Arg107 is even conserved in insects and worms. The alignment was 
performed with Clustal W. Bird: Gallus gallus; fish: Danio rerio; frog: Xenopus laevis; insect: Drosophila 
melanogaster; nematode: Caenorhabditis briggsae. (D) Crossed-eye stereo representation of dimeric human 
SSBP1 X-ray structure (pdb code 1S3O) with the residues of basic patch B (Arg38, Lys104, Arg107 of 
subunit A, and pseudo-symmetry related Arg28 of subunit B, according to Yang et al., 1997) as well as the 
mutated Ser141 in stick representation; mutated residues in magenta, the two other basic residues in blue. 
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FIGURE 7: SSBP1 and OPA1 expression in mouse retina. 
DAB immunohistochemistry of wax sections from 2-month-old mouse eye showing that Ssbp1 is abundant in 
the retina. OPA1 is primarily expressed in the GCL, IPL, INL, and OPL. Sections were counterstained with 
haematoxylin (blue). Panel shows a control section (primary antibody omitted). GC= ganglion cell layer, 
IPL= inner plexiform layer, INL= inner nuclear layer, OPL= outer plexiform layer, ONL= outer nuclear layer, 
PRL= photoreceptor layer, RPE= retinal pigment epithelium. 
403x204mm (72 x 72 DPI) 
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FIGURE 8: Mitochondrial staining in SH-SY5Y cells. 
(A) Shows a merged fluorescence image of mitochondria labelled with mitotracker red (B) and anti-ssbp1 
(C). Arrows indicate the presence of brightly stained green punctuate structures, which may indicate the 
presence of mitochondrial nucleoids. (D) The merged image of anti-ssbp1 and anti-TFAM shows dots that 
were co-located and each dot may represent TFAM/mtDNA complex/nucleoid. Immunolabelling using anti-
ssbp1 (E) stained in a pattern associating with the mitochondria. Immunolabelling using anti-TFAM (F) 
showed a granular pattern in the cytoplasm. Scale 25  m for A-C panels and 20  m for D – F panels. 
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Supplementary Table 1. Clinical characterisation of affected family members.
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3-8# M Late Childhood (9) 64 BE 1.78 BE 1/17 NA + (9) + (NA) + (NA) Renal problems NA
3-16# M Early Childhood (3) 44 BE 1.0 NA ET’ RE + (3) + (NA) - NA NA
4-3# F NA 25 BE 1.0 NA Normal + (NA) - - Renal failure NA
4-7 F Early Childhood (2) 25 BE 1.3 BE 5/17 Normal + (2) - - Fit and healthy NA
4-8 M Early Childhood (4) 27 BE 1.0 NA Normal + (4) - - Fit and healthy NA
4-12 F Early Childhood (3) 55 BE 3.0 NA XT′ + (3) + (36) + (49)
Hypothyroidism
Diabetes type II
Hyperlipidaemia
Age 46: ERGs; rod-cone dysfunction. PERG P50 undetectable; severe 
macular involvement.
PVEP undetectable; possible optic nerve dysfunction.
4-14 F Early Childhood (5) 54 BE 3.0 NA XT′ LE + (5) + (45) + (46)
Hypothyroidism
Diabetes type II
Hypertension
Cataracts surgical 
treatment at the age of 46
Age 45: ERGs; severe photoreceptor dysfunction. PERG P50 undetectable; 
severe macular involvement.
PVEP and flash VEP undetectable; probable optic nerve dysfunction.
4-18 F Early Childhood (1) 48 BE 2.0 NA Normal + (1) + (48) + (48) HypothyroidismRenal failure NA
5-2# F Early Childhood (3) 18 BE 1.3 NA XT’ RE + (3) + (16) + (17) NA Age 18: ERGs; rod-cone dysfunction. PVEP subnormal; possible optic nerve dysfunction.
5-5 M Adolescence (15) 26 RE 0.3LE 0.4
RE 4/17
LE 5/17 Normal + (15) + (17) + (24) Asthma
Age 18 and 26: ERGs; rod-cone dysfunction. PERG P50 short peak time, 
N95:P50 ratio reduced & PVEP abnormal; retinal ganglion cell/optic nerve 
dysfunction.
Fa
m
ily
 1
5-12 M Early Childhood (3) 18 RE 0.4LE 0.3
RE 1/17
LE 1/17 Normal + + - Fit and healthy
Age 7: Flash ERGs normal. PERG P50 short peak time, N95:P50 ratio 
reduced & PVEP abnormal; retinal ganglion cell/optic nerve dysfunction.
2-2 M Late Childhood (9) 46 BE 0.18 BE  6/17 Normal + (9) N. + Fit and healthy Age 46: ERGs normal. PVEPs slightly broad in shape but of normal timing.  Possible optic nerve dysfunction
2-3 M Middle Childhood (7) 50 BE 0.78 BE 3/17 Normal + (7) N. + Hypertension Age 49: ERGs normal.PVEP delayed and subnormal. Possible optic nerve dysfunction
2-4 F Mature Adulthood(4th decade) 54
RE 0.0
LE 0.22
BE 3/17 Normal +(54) N. N. Fit and healthy NA
3-1 M Middle Childhood (7) 7 BE 0.48 BE 1/17 Normal + (7) N. N. Fit and healthy Age 7: FVEP and ERGs normal. 
Fa
m
ily
 2
3-4 M Adolescence (17) 19 RE 0.18LE 0.6
BE 1/17 Normal + (17) N. + Fit and healthy Age 19: ERGs normal. PERG N95:P50 ratio subnormal. PVEP and FVEPs undetectable. Optic nerve/retinal ganglion cell dysfunction
Si
ng
le
to
n 
(F
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ily
 3
)
2-3 M Middle Childhood (7) 57 BE 1.3 BE 0/17 Normal + (7) +(NA) +(14) Hypothyroidism Age 52:. ERGs; rod-cone dysfunction. PERG N95:P50 ratio reduced & PVEP abnormal; retinal ganglion cell/optic nerve dysfunction
Si
ng
le
to
n 
(F
am
ily
 4
)
2-1 M Mature Adulthood(2nd decade) 45 BE 1.0 NA Normal + (12) NA NA Fit and healthy NA
# - notes reviewed; F – female; M – male; BE – both eyes; RE – right eye; LE – left eye; LogMAR – logarithm of the minimum angle of resolution; NA – not applicable; XT′ - exotropia; ET′  - esotropia.
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